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s u m m a r y
Overnutrition and sedentary lifestyle result in overweight or obesity deﬁned as abnormal or excessive fat
accumulation that may impair health. According to the WHO, the worldwide prevalence of obesity nearly
doubled between 1980 and 2008. In 2008, over 50% of both men and women in the WHO European
Region were overweight, and approximately 23% of women and 20% of men were obese. Comprehensive
diagnostic and therapeutic approaches should include nutritional treatment to favor the best metabolic
and nutritional outcome, as well as to induce potential disease-speciﬁc beneﬁts from selected nutritional
regimens. Obesity is usually accompanied by an increased muscle mass. This might explain why obesity,
under particular circumstances such as cancer or high age, might have protective effects, a phenomenon
named the ‘obesity paradox’. However, loss of muscle mass or function can also occur, which is
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2Multidisciplinary
Weight maintenance
associated with poor prognosis and termed ‘sarcopenic obesity’. Therefore, treatment recommendations
may need to be individualized and adapted to co-morbidities. Since obesity is a chronic systemic disease
it requires a multidisciplinary approach, both at the level of prevention and therapy including weight loss
and maintenance. In the present personal review and position paper, authors from different disciplines
including endocrinology, gastroenterology, nephrology, pediatrics, surgery, geriatrics, intensive care
medicine, psychology and psychiatry, sports medicine and rheumatology, both at the basic science and
clinical level, present their view on the topic and underline the necessity to provide a multidisciplinary
approach, to address this epidemic.
© 2016 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights reserved.
1. Introduction
1.1. Deﬁnition of obesity
Recently, the ESPEN society has published a consensus on new
terminology for clinical nutrition, in which obesity and related
terms as well as related diagnostic procedures have been deﬁned
[1]. According to this terminology, nutrition disorders and
nutrition-related conditions are divided into malnutrition/under-
nutrition and overnutrition resulting in overweight or obesity
(Fig. 1). Overweight and obesity are deﬁned as abnormal or
excessive fat accumulation that may impair health (WHO 2000).
Apart from fat accumulation, adipocyte dysfunction may occur,
leading tometabolic changes enhancing the risk of chronic diseases
and cancer. Classiﬁcation of overweight and obesity in adults is
achieved through the use of body mass index (BMI), which is a
simple index of weight-for-height (Table 1).
1.2. Sarcopenic obesity
According to the new ESPEN consensus on terminology [1]
sarcopenia is a syndrome characterized by the progressive and
generalized loss of skeletal muscle mass, strength and function
(performance) with a consequent risk of adverse outcomes [2e4].
Whilst often a phenomenon of the ageing processes (primary sar-
copenia) it may also result from pathogenic mechanisms (second-
ary sarcopenia) that are disease-related, physical activity-related
(e.g. disuse) or nutrition-related (e.g. protein deﬁciency). Diag-
nostic criteria for sarcopenia have not been ﬁrmly established to
date. Sarcopenic obesity is deﬁned as obesity in combination with
sarcopenia that occurs for example in older individuals, in those
with type 2 diabetes mellitus (T2DM) or chronic obstructive pul-
monary disease (COPD), and in weight-losing obese patients with
malignant disorders. Mechanisms include inﬂammation and/or
inactivity induced muscle catabolism in obese patients [5,6]. The
condition can occur virtually at all ages.
1.3. Obesity as a chronic systemic disease
Obesity is a chronic systemic disease requiring a multidisci-
plinary approach (Fig. 2). This fact is not clearly pointed out in the
current deﬁnitions of obesity. Data indicate that obesity is hardly
reversible spontaneously and is associatedwith increasedmortality
[7,8]. Despite some genetic and epigenetic inﬂuences, obesity is an
acquired disease that depends on lifestyle factors such as over-
eating and low physical activity [9]. This makes e at all ages e
obesity prevention as well as obesity therapy a realistic albeit
difﬁcult option. There is no critical time for the development of
obesity, and previous weight history is not consistently a dominant
factor in determining subsequent weight gain [10].
Obesity affects almost every organ system of the body including
the endocrine, gastrointestinal (GI), cardiovascular (CV), and cen-
tral nervous systems. Obesity challenges not only endocrinologists,
gastroenterologists, nephrologists and cardiologists, but also pe-
diatricians and geriatrists, surgeons and intensivists, orthopedists
Fig. 1. Nomenclature of overnutrition, overweight and obesity. For explanations see
text.
Table 1
Classiﬁcation of overnutrition.
Classiﬁcation Subclassiﬁcation Criteria
Overweight BMI 25e29.9 kg/m2
Obesity BMI 30 kg/m2
Obesity grade I BMI 30e34.9 kg/m2
Obesity grade II BMI 35e39.9 kg/m2
Obesity grade III BMI 40 kg/m2
Abbreviation: BMI, body mass index, deﬁned as a person's weight in kilograms
divided by the square of their height in meters.
Fig. 2. Obesity is a chronic systemic disease requiring a multidisciplinary approach. For
explanations see text.
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3and psychologists, nutritionists and sports medicine specialists. A
multidisciplinary approach is therefore warranted to prevent and
manage obesity; however, this is often not the reality. The lack of
comprehensive and multidisciplinary approaches might be one
explanation why we still fail to control the obesity epidemic.
Comprehensive diagnostic and therapeutic approaches should
include nutritional treatment to favor the best metabolic and
nutritional outcome, as well as to induce potential disease-speciﬁc
beneﬁts from selected nutritional regimens [11]. Disease-speciﬁc
therapeutic decisions are often needed in terms of nutrient selec-
tion, interactions, timing and duration of administration. ESPEN
traditionally hosts and favors interactions between nutritionists
from different specialties, whose expertise can provide the best
multidisciplinary approach to ensure optimal choices for nutri-
tional assessment, treatment and follow-up. In the present position
paper, experts from different specialties aim to contribute to the
understanding of obesity to foster the multidisciplinary approach
and to ensure optimal prevention and management of this major
global health challenge.
2. Clinical challenges
2.1. Obesity from an endocrinologist's view
Obesity is often associated with several endocrine alterations.
Insulin resistance is related to impaired glucose disposal in skeletal
muscle and adipose tissue, as well as excess hepatic glucose pro-
duction. Obesity-associated insulin resistance is at least partly
initiated by excess glucose and lipid availability, which may pri-
marily impact gut microbiota leading to unfavorable changes in gut
permeability contributing to sustained systemic inﬂammation.
Excess lipid and its deposition may lead to enhanced reactive ox-
ygen species generation, oxidative stress and inﬂammation at
systemic and tissue level, with activation of intracellular pathways
inhibiting insulin signaling [12,13].
Insulin resistance and hyperinsulinemia also play a central role
in the pathogenesis of the metabolic syndrome (MetS), as deﬁned
by at least three-out-of-ﬁve clustered abnormalities among high
waist circumference, high blood pressure, high glucose and dysli-
pidemia with high triglycerides and low HDL-cholesterol. Although
diagnostic thresholds still vary among different deﬁnitions, the
MetS is unequivocally associated with strong increments in CV
morbidity and mortality, thereby representing a potential useful
screening tool to assess cardiometabolic risk in overweight-obese
patients. The potential onset of T2DM is further associated with
increased morbidity and mortality, due to its chronic complications
and increased risk of CV events, surgery, infection and other com-
mon clinical conditions [14].
Additional relevant endocrine alterations in obese individuals
include altered sex hormones and gonadal function. Male obese
patients may present with low plasma testosterone, low sex hor-
mone binding globulin and hypogonadism that may also directly
contribute to insulin resistance [15]. Female patients may present
with the polycystic ovary syndrome, including hyperandrogenism,
oligo-amenorrhea and altered ovarian structure [16]. Reduction of
insulin resistance and circulating insulin through lifestyle inter-
vention and pharmacological treatment have been reported to
improve hormonal patterns and fertility, and to reduce the high risk
of T2DM in the polycystic ovary syndrome population [16].
Cortisol has negative metabolic effects in obese individuals but
baseline cortisol and ACTH levels appear, however, to be unaltered
by obesity per se. On the other hand, enhanced responses to
stimulatory tests are reported, particularly in patients with MetS
[17]. Thus, the role of altered cortisol production and excess avail-
ability has potential clinical relevance in selected patient groups.
Adipose tissue and the gut have been only recently appraised, or
re-appraised, as endocrine tissues regulating energy homeostasis.
For example, deﬁciency of the adipose anorexigenic hormone lep-
tin causes familial monogenic obesity. Moreover, obesity is associ-
ated with leptin resistance and excess circulating hormone may be
paradoxically involved in obesity-associated metabolic complica-
tions [18]. Several additional adipokines modulate energy balance,
intermediate metabolism and blood pressure: as a relevant
example, the renin-angiotensin-aldosterone system is also
expressed in adipose tissue and its activation may contribute to
hypertension and renal complications [19].
Gut hormones also include appetite regulators such as the
duodenal anorexigenic hormone and stimulator of insulin secretion
glucagon-like peptide 1 (GLP-1). GLP-1 effects and plasma levels
may be impaired in obesity and T2DM, and its pharmacological
activation has become a relevant option in their treatment [20]. On
the other hand, the orexigenic hormone ghrelin may contribute to
excess food intake in its acetylated form, and regulation of ghrelin
acylation is a potential target for the treatment of complicated
obesity [21].
Finally, primary endocrine diseases may cause secondary
obesity, such as Cushing syndrome, insulinoma and hypopituita-
rism with low growth hormone. Hypothyroidism should be ruled
out in initial screening of obese individuals due to its relatively high
prevalence in the general population.
In conclusion, obesity is a challenging condition whose endo-
crinological implications remain partly underappreciated. The
impact of obesity on several relevant endocrine networks should be
considered.
2.2. Obesity from a gastroenterologists's view
Gastroenterologists often do not consider obesity as their ﬁeld
of interest and experience. Obesity and related diseases are
generally assigned to general practitioners, endocrinologists and
diabetologists, despite the fact that the GI tract is the site of food
uptake (and thus also a potential site for intervention against
obesity) and that virtually all organs the gastroenterologist con-
cerns to such as liver, gallbladder, pancreas and intestine are
afﬂicted by obesity. Liver develops steatosis and inﬂammation,
gallbladder motility is reduced and risk of stone formation
enhanced, endocrine pancreas functions become impaired, and
intestinal microbiota changes in the course of disease. For more
details on the role of the intestinal microbiota in obesity see
“Obesity and the gut microbiota”, a section later.
The intestine seems to be involved in the regulation of food
intake and thus in the pathophysiology of obesity. Intestinal
motility, hormones and nerve signals have been identiﬁed as
crucial signals that either locally in the bowels or centrally in the
brain affect food intake and satiety that ﬁnally regulate body
weight and body composition [22,23]. Obesity is a risk factor for a
variety of GI diseases, e.g. gastro-esophageal reﬂux, Barrett's
esophagus, and neoplastic diseases such as esophageal adenocar-
cinoma, colorectal carcinoma, and gallbladder cancer. Intestinal
targets could be of relevance for future nutritional or pharmaco-
logical treatment of obesity and related diseases. For example,
recent studies revealed that orally administered glycine-b-mur-
icholic acid, an inhibitor of the farnesoid X receptor in the gut,
improves metabolic parameters in mouse models of obesity [24].
Thus, gastroenterologists could contribute to the topic of obesity,
both on the research level and the clinical level, the latter by
diagnosing obesity related GI disorders and prescribing supportive
therapies.
The liver plays a central role in obesity pathophysiology. Liver
steatosis has been recognized as an early indicator of the obesity-
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4associated MetS [25]. This type of liver steatosis, also named non-
alcoholic fatty liver disease (NAFLD), is a risk factor for cirrhosis
and hepatocellular carcinomas for which obese patients at risk
need to be screened [26]. See also “The gut-liver-axis” a section
later.
The only activities that gained some interest among practicing
gastroenterologists are endoscopic approaches such as placing
gastric balloons into the stomach or plastic tubes into the duo-
denum to reduce food intake prior to a surgical intervention [27].
Gastroenterologists could do much more in the ﬁeld of obesity.
First, the gastroenterologists have a particular proximity to clinical
nutrition e and indeed many clinical nutritionists have a GI
background e, second, gastroenterologists have direct access to
the intestine allowing them to study human GI pathophysiology in
the obese, and third, gastroenterologists know about most rele-
vant organs involved in obesity erelated diseases such as the liver
and its pathophysiology predestining them to study e.g. NAFLD.
Step by step, some gastroenterologists realize this potential and
started to work with great success in this ﬁeld. However, much
more gastroenterologists need to be involved in this ﬁeld in the
future.
2.3. Obesity from a nephrologist's view
Obese patients undergoing chronic dialysis present a greater
survival than lean patients. In contrast, obesity is a condition
associated with renal worsening and progression of renal disease
towards dialysis. Obesity aggravates hypertension, a prominent
kidney disease progression factor [28]. Obese patients have
increased proteinuria, independent from the causal of renal dis-
ease, in response to protein and salt overload [29]. Interestingly,
proteinuria improves after bariatric surgery and concomitant
weight loss [30]. A high BMI is therefore deleterious with respect to
metabolic disorders and progression of renal disease.
A state of glomerular hyperﬁltration is present in the obese and
will induce glomerular slit membrane stress, which can be moni-
tored by microalbuminuria measurement [31]. This is later fol-
lowed by a more pronounced albuminuria, consequence of
irreversible glomerular hyalinosis and sclerosis. At this stage, renal
function has already decreased bymore than 50%, corresponding to
chronic kidney disease (CKD) stage 3. High blood pressure is also
frequently present and further aggravates the loss of renal function.
Thus, there is a continuous spectrum from obese adults without
kidney disease towards progressive renal lesions leading to severe
CKD and the need for dialysis.
Links between obesity and CKD have been recently unraveled.
Intestinal protein degradation products such as p-cresyl sulfate,
indoxyl-sulfate and trimethylamino-oxide enter the bloodstream
and will accumulate in CKD patients [32] and exert a toxic effect on
adipocytes. These cells will undergo a pro-inﬂammatory phenotype
and promote insulin resistance, an early event reported during CKD
which is aggravated by overweight [33]. Other metabolic abnor-
malities may also worsen renal function such as dyslipidemia,
which is per se a consequence of proteinuria. Thus, a number of
vicious circles are present in CKD and some are directly triggered by
obesity. Finally, the GI microbiota has been recently shown to be
altered during CKD. Not only is the number of bacteria species
reduced, but its spectrum also expresses a pro-inﬂammatory
pattern [34].
In the course of CKD, body composition can be altered through
water retention (nephrotic syndrome, cardiac insufﬁciency). This
complicates body composition measurements during CKD while
using bio-electric impedance analysis (BIA). Fat and muscle mass
might also be estimated inadequately [35]. The concept of meta-
bolically healthy overweight individuals without MetS or CV
complications, is a promising ﬁeld [36], but to date no data are
available in obese CKD patients.
During maintenance dialysis, death risk is markedly increased
and protein/energy wasting is a greater death risk than overweight
during the ﬁrst years of dialysis [37]. This explains the paradox of
better survival in obese dialysis patients [38]. In elderly dialysis
patients, both increase and decrease in BMI are associated with an
increased mortality, suggesting that weight should be kept stable
over time. In overweight patients with early CKD, efforts should be
done to reduce obesity that aggravates proteinuria and fastens CKD
progression. A successful weight loss is able to reverse proteinuria, a
well identiﬁed independent kidney disease progression factor [39].
Obesity is linked to a greater rejection rate in transplant patients
and weight gain, a frequent condition after transplantation, should
be avoided by adherence to a dedicated nutritional care plan [40].
2.4. Obesity from a pediatrician's view
Obesity is the most prevalent pediatric nutritional disorder
worldwide [41]. From a disorder of afﬂuent societies, obesity is
increasingly recognized in developing countries and turns malnu-
trition, which includes both under- and over nutrition, to a disorder
where both ends of the spectrum should be addressed. Recently,
prevalence of overweight and obesity in children and adolescents
in developed countries was estimated at 23.8% for boys and 22.6%
for girls [42]. In developing countries the prevalence was estimated
as 12.9% of boys and 13.4% of girls [42]. While reports indicate that
obesity in children is a major public health hazard [43,44], there is
no deﬁnite consensus on the deﬁnition of pediatric obesity.
In contrary to adults, BMI is dependent on age, which mandates
that BMI data in children are plotted on age and sex speciﬁc charts.
TheWHO deﬁnes overweight as a Z score above 2 and obesity as a Z
score above 3. Determination of obesity depends on the growth
charts used, e.g. National growth charts or the WHO growth stan-
dards, resulting in different cut off values [45].
The rationale for treating obesity already in childhood is not
limited to its relationship with obesity in adulthood, but spans to
the multiple complications associated with obesity (Table 2). Thus,
pediatricians should identify obese children and evaluate the
presence of complications including but not limited to hypercho-
lesterolemia, diabetes and hypertension.
Prevention and treatment of obesity focuses on life style in-
terventions (mainly increase in physical activity and reduction of
sedentary activities), on diet and behavioral programs. The con-
clusions of the 2009 Cochrane analysis are still valid stating that
“While there is limited quality data to recommend one treatment
program to be favored … combined behavioral lifestyle in-
terventions compared to standard care or self-help can produce a
signiﬁcant and clinically meaningful reduction in overweight in
children and adolescents …. high quality research that considers
psychosocial determinants for behavior change, strategies to
improve clinician-family interaction, and cost-effective programs
for primary and community care is required” [46].
When life style modiﬁcation fails, the need for drug treatment in
pediatric obesity is hampered by limited understanding of patho-
physiology, lack of agreement on dosing, adherence, ethical con-
siderations and post marketing complications that terminated the
use of previously approved drugs. Currently there is only one drug,
orlistat, that is approved for treatment of adolescents. It reduces fat
absorption by up to 30%, and provides an additional BMI loss of
0.5e4 kg/m2 over a period of 12 months, but is only suitable for
adjuvant therapy that accompanies behavioral interventions tar-
geting effective lifestyle changes [47].
As in adults, bariatric surgery is a promising treatment of
morbid obesity, and is gaining popularity in morbidly obese
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5adolescents. Yet, a recent review [42] identiﬁed only one random-
ized controlled trial evaluating laparoscopic adjustable gastric
banding. This trial demonstrated better weight loss, leading the
authors to conclude that “Results do not provide enough data to
assess efﬁcacy across populations from different countries, socio-
economic and ethnic backgrounds, who may respond differently”
[42].
In summary, pediatric obesity is a research as well as clinical
challenge as it constitutes a major health hazard. A better under-
standing of its pathophysiology, deﬁnitions, diagnosis, as well as
evaluation of the effect of various treatment modalities with pro-
longed follow up is therefore urgently needed.
2.5. Obesity from a surgeon's view
A surgeon's focus is directed towards reduction of postoperative
complications. A well-known association between preoperative
functional health status and postoperative morbidity and mortality
has been recently conﬁrmed [48]. Complications prolong hospital
length of stay, with delay in recovery and rehabilitation of the pa-
tient. Additionally, it will be a ﬁnancial burden for the hospital and
the health care system. Besides malnutrition and despite the
obesity paradox, which might be true for subgroups of the popu-
lation but not for the general population [49], obesity remains a
signiﬁcant metabolic risk factor for anastomotic leaks, surgical site
infections, and poor outcome [50,51]. The risks of obesity and the
MetS are enhanced by co-existing diabetes [51]. Therefore, an
appropriate management of adjustable risk factors is mandatory.
For any elective non-tumor surgery, especially abdominal surgery,
risk minimization may be achieved by preoperative weight
reduction and optimal treatment of comorbidities. In bariatric
surgery, preoperative weight loss by a very low calorie diet has
been shown to facilitate the procedure and to decrease the risk for
complications [52]. Aiming at ‘Enhanced Recovery After Surgery’
(ERAS) for severely obese patients, new “prehabilitation” strategies
for the adjustable risk factors in elective benign and non-bariatric
abdominal surgery need to be explored [53].
Beneﬁts and risks have to be critically balanced in all surgical
procedures. Nowadays, bariatric and metabolic surgery has been
well established and considered the treatment of choice in morbid
obesity. Although the surgical complication rate is very low and the
beneﬁts are very convincing, severe long-term complications like
protein malnutrition that may even require parenteral nutrition
(PN) may occur. Current guidelines mandate supplementation after
all bariatric procedures, with dose stratiﬁcation according to the
surgical procedure [54]. The ESPEN special interest group “Chronic
intestinal failure” has recently opened a chapter for bariatric sur-
gery. According to the latest Cochrane analysis based on twenty-
two trials, the long-term effects of bariatric surgery remain un-
clear [55].
Recently, a decisioneanalytic model to estimate the balance
between treatment risk and beneﬁts for severely obese patients
with diabetes was developed. For a typical 45 y old woman with
diabetes and a BMI of 45 kg/m2, the gain-of-life-expectancy was 6.7
years. However, this decreases with increasing BMI, and in patients
with a BMI of 62 kg/m2 and higher the non-surgical treatment may
be associated with greater life expectancy compared to the surgical
intervention [56]. There has been some considerable nihilism
regarding the success of conservative treatment options, and there
is a shortage of programs and controlled data as well [57e59].
Promising results with comparable weight loss have been
conﬁrmed by own data (manuscript in preparation). In an inten-
siﬁed conservative program using very low calorie diet (VLCD)
weight reductions of more than 20% of initial body weight loss, and
40% of excessive body weight loss, could be achieved within 12
months of intervention. These changes are accompanied by an
improvement in hypertension, diabetes and quality of life. There-
fore, even in morbid obesity conservative treatment should be not
excluded per se. It may be easier to decide for surgery taking into
account some risks and potential disadvantages if all available
conservative options have been maximally exploited.
2.6. Obesity from a geriatrician's view
Obesity in people >70 years of age is not unambiguously
negative. On the contrary, prospective population based cohort
studies indicate that overweight, i.e. BMI 25e30 kg/m2 in particular,
but sometimes also obesity (BMI > 30 kg/m2) is associated with
improved survival when compared to being “normal-weight” (BMI
18.5e25 kg/m2) [60]. This observation is usually referred to as the
‘obesity paradox’ that is also present in chronic diseases [61]. The
reasons for this reversed epidemiology are not clear. Selection
could be one, meaning that people with dysmetabolic obesity,
mainly in the form of central obesity (i.e. enhanced waist circum-
ference) which is linked to the MetS, die at younger age. Thus,
people with a metabolically less active fat mass are left to survive
into older age. In such cases, overweight/obesity may reﬂect
absence of disease, rather than representing a healthy condition per
se. An energy reserve to use in case of incident disease could be
beneﬁcial in the “geriatric” period of life when acute and chronic
diseases commonly occur. Age-related osteoporotic height reduc-
tion alone may increase BMI up to one kg/m2 unit and add to the
obesity paradox. At old age underweight, already deﬁned as BMI
<22 kg/m2, is far more deleterious than obesity. Still, severe obesity
and abdominal obesity are never beneﬁcial, not only reducing
survival but also contributing to disability [60].
By ageing, anabolic activities decrease and degenerative pro-
cesses become more prominent. Secretion of anabolic hormones;
Table 2
Complications of overweight and obesity in children and adolescents.
Category Complication
Psychological Impaired body perception
Isolation
Aggression
Drugs and alcohol abuse
Bulimia
Smoking
Cardiovascular Atherosclerosis
Hyperlipidemia
Endothelial dysfunction
Hypertension
Left ventricular hypertrophy
Respiratory Obstructive sleep apnea
Asthma
Hypoventilation
Endocrine Metabolic syndrome (MetS)
Type 2 diabetes mellitus (T2DM)
Polycystic ovary syndrome
Premature adrenarche
Menstruation abnormalities
Thyroid gland dysfunction
Orthopedic Slipped capital femoral epiphysis
Early degenerative arthritis
Coxa Vara
Blount disease (Adolescent tibia vara)
Perthes disease
Back pain
Miscellaneous Reduced quality of life
Non alcoholic fatty liver disease (NAFLD)
Cholesterol gallstones
Pseudo tumor cerebri
Colon cancer
Breast cancer
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6e.g. testosterone, estrogen and growth hormone is reduced. Mito-
chondrial DNA mutations enhance apoptosis, neuromuscular syn-
aptic damages and age-induced increased inﬂammatory activity
will further promote catabolic effects on mainly muscle cells. These
processes may lead to sarcopenia, which is the combined presence
of reduced muscle mass and reduced muscle strength or perfor-
mance. As long as appetite is preserved and combined with
reduced physical activity in older adults, there will be an accumu-
lation of subcutaneous and ectopic fat. This muscle and fat mass
disproportion may end up in a condition called ‘sarcopenic obesity’
[6,62].
The deﬁnition of sarcopenic obesity is pending but is obviously a
combination of the two syndromes. Cohort studies in older pop-
ulations have reported sarcopenic obesity prevalences ranging
from 1 to 15%, the large variation is due to different settings, pop-
ulations and deﬁnitions [5,63]. Sarcopenia is deleterious, whereas
elevated BMI and preservedmusclemass is potentially protective at
old age. Themajor current perception supports the assumption that
sarcopenic obesity is associated with negative health outcomes at
old age [64].
Under circumstances whenweight loss is clinically justiﬁed, like
in diabetes, MetS, joint disorders or other disabilities, weight loss
programs could well be successful, but should include exercise in
order to protect from loss of muscle mass and to enhance the
positive metabolic effects from the weight loss [65].
2.7. Obesity from an intensivists's view
Obesity in critically ill patients is associated with increased
morbidity but not increased mortality, because intensive care unit
(ICU) patients are catabolic and obese therefore may use their
excessive fat stores as energy source while preserving the muscle
reserve [66]. A signiﬁcant source of protein and lipids, enough trace
elements and vitamins, and substrates that maintain the GI barrier
and the immune system should be provided. However, strong ev-
idence regarding energy and substrate requirements of obese pa-
tients fed by enteral nutrition (EN) or PN is still missing and the
recommendations are at the level of expert opinion [67].
Indirect calorimetry allows the determination of individual en-
ergy requirements of obese patients. For a BMI between 40 and
80 kg/m2, the required resting energy expenditure (REE) varies in
mean between 1895 and 2635 kcal/day [68]. Obese critically ill
cancer patients have signiﬁcantly higher nutrition requirements
than the current guideline recommendations indicate [67], reach-
ing 28.7 ± 5.2 kcal/kg of ideal body weight (IBW)/day. Port and
Apovian [69] recommend to measure energy needs by calorimetry
and to administer 100% of these needs by EN or PN. If indirect
calorimetry is not available, prediction equations such as the Penn
University formula could be used providing an accuracy of around
65% [70].
Comparing the administrating of a hypocaloric diet (between
3 kcal/kg IBW/day to 14 kcal/kg current body weight (CBW)/day)
versus a normo-caloric diet (25e36 kcal/kg IBW/day), both com-
bined with a high protein intake (1.8e2.2 g/kg IBW/day), hypo-
caloric regimen showed slight advantages such as less insulin
requirements, better wound healing and decreased ICU stay and
antibiotic days [71]. Experts recommended that the goal of an EN
regimen should not exceed 60e70% of target energy requirements
or 11e14 kcal/kg CBW/day (or 22e25 kcal/kg IBW/day) [72]. If
permissive hyponutrition (10e14 kcal/kg CBW/day) is prescribed,
the enteral route should be preferred. Protein should be provided in
a range >2.0 g/kg IBW/day for obesity class I and II patients (BMI
30e40 kg/m2), and >2.5 g/kg IBW/day for obesity class III patients
(BMI > 40 kg/m2). A recent study showed that obese patients were
fed in delay in comparisonwith patients with lower BMI [73]. These
ﬁndings are of importance since obese patients suffer from loss of
lean body mass and need early enteral feeding to prevent negative
energy balance and nitrogen balance. If the needs cannot be
covered by the enteral route, the parenteral route can be used in a
supplemental or exclusive manner and has been shown to be safe
[74].
With the increase in bariatric surgery, related complications
including anastomosis leak, narrowing lumen and too small bowel
absorption surface are increasing the indication for PN. The nutri-
tional regimen should be guided by indirect calorimetry and
include a high protein intake (1.5e2 g/kg IBW/day).
In summary, the obese critically ill patients should be fed ac-
cording to his requirements and if indirect calorimetry is not
available, according to the Penn State equation.
2.8. Obesity from a psychologist's view: the way to long-term
success
To identify and offer optimal nutritional care beyond weight-
reducing calorie-restricted diets it is important to consider and be
supported by psychological and behavioral strategies that offer
support in the adherence of particular diets over the short and
longer term. The patients' psychological and mental state such as
e.g. motivational and emotional condition, as well as the social
environment can determine successful behavior change [75]. On
one hand, the social environment needs to be able and willing to
adjust to changes in the patient's diet and lifestyle to increase the
likelihood of long-term success. On the other hand, to change
eating and exercise habits is difﬁcult and practicing skills such as
stress management with problem-solving techniques, cognitive
restructuring to improve self-control, and self-monitoring to sup-
port lifelong changes are essential for both weight loss and weight
loss maintenance [76,77].
Furthermore, psychologists and psychotherapists should be part
of the multidisciplinary team approach aimed at optimal treatment
and follow-up. Epidemiological studies show a positive association
between obesity and mood and anxiety disorders [78]. Existing
comorbidities have consequences for both pharmacological as well
as psychological treatment options. Every obese patient is unique
and might beneﬁt from psychological support along the way of
treatment and weight loss maintenance. Not only the body and its
nutritional needs should be addressed but also the mindset and the
patients' psychological well-being and quality of life.
2.9. Cognitive function and psychiatric co-morbidities in obesity
The medical consequences of obesity are well recognized since
years, but the cognitive consequences have been studied only
recently. Cognitive function refers to the processing, integration,
storage and retrieval of information. It includes perception, atten-
tion, memory and executive function. There are no clear recom-
mendations about the extent and type of follow-up needed to
evaluate cognitive function over time in obese individuals.
Whether cognitive function deﬁcit and mental health disorders
(MHD) are a cause or consequence of obesity is still a subject of
debate.
In the groups of 4e18 and 19e65 years old people, obese in-
dividuals have signiﬁcantly poorer cognitive indices comparedwith
normal weight individuals. The most consistent ﬁnding is poor
results in tests of executive function. Obesity may predict cognitive
decline but changes in weight itself does not consistently predict
changes in cognition. In the elderly age group of 66e95 years, the
relation between obesity and cognition is less clear. The positive
association of obesity and cognitive dysfunction is independent of
socio-economic factors, depression and CV factors. Obesity by itself
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with other CV risk factors such as hypertension, the deﬁcit in
cognitive function is more pronounced suggesting an additive ef-
fect. Since obesity is a risk factor for many components of the MetS,
early treatment and prevention are mandatory to minimize the
detrimental effect of the MetS on cognitive function [79,80]. The
inverse relationship between low levels of executive function and
motor function with increased BMI was shown in longitudinal
studies [81e83].
Obesity is coincident with MHD in 45% of MDH cases. In-
dividuals with schizophrenia, bipolar disorder, depression, anxiety,
attention deﬁcit/hyperactivity disorder (ADHD) have a higher
prevalence of both obesity and MetS compared to the general
population. Many of the relationships between MetS and MHDs are
sex-dependent. Overweight and obese women have increased
prevalence of anxiety, major depressive disorder and both child-
hood and adult ADHD, while obese men do not show the same
trends [80]. Individuals with depression and emotional dysregu-
lation commonly have a preference for sweeties and fatty food [84].
Obesity occurring in the midlife is associated with an increased risk
of dementia, such as Alzheimer's disease, in later life [85]. As for
obesity and cognitive function, the bidirectional relationship be-
tween obesity and MHD may contribute to resistance against
treatment.
Extremely high fat diet with 74% kcal as fat impairs cognitive
function in sedentary men and is involved in mood disorders
[80,83]. Weight loss, secondary to hypocaloric diet or bariatric
surgery, has been shown to result in an improvement of memory
performance but not executive function [83]. Neuroinﬂammation,
genetic vulnerability, dysregulation of the hypothalamic-pituitary-
adrenal (HPA) axis, or neuropeptides such as dopamine, serotonin,
neuropeptide Y, corticotropin-releasing factor, and disturbance of
the endocannabinoid system are potential mechanisms linking
obesity and obesity-associated metabolic disorders with cognitive
function [80,85]. Obesity is associated with low-grade inﬂamma-
tion in peripheral tissues and in the circulation as well as in the
brain, mainly in the hypothalamus. The systemic and central
inﬂammation may converge to dysregulation of feeding and
cognitive function.
In conclusion, obesity is associated with impaired cognition,
mainly executive function, but this relationship is bidirectional
since reduced cognitive function may be the cause and conse-
quence of obesity [86]. The length of exposure to metabolic dis-
turbances needed to induce cognitive dysfunction is not known but
could explain the incomplete resolution of cognitive impairment
after weight loss.
2.10. Obesity impact on physical ﬁtness
Physical ﬁtness refers to a state of well-being achieved by
adequate nutrition, physical activity, and rest. Obesity has a major
impact on health-related physical ﬁtness, which encompasses body
composition, muscle strength and endurance, cardiorespiratory
ﬁtness (CRF) and ﬂexibility. Several methods for assessing health-
related physical ﬁtness are available (Table 3).
Obese individuals can have a different amount of muscle mass
or fat distribution, which affects outcome. A high abdominal
adiposity has been associated with metabolic risk factors, CV dis-
eases, cancer, sleep apnea and mortality, and also with a low
physical activity level [87]. However, a high BMI and percentage
total body fat have surprisingly a protective impact in the elderly
and in conditions such as CV disease, cancer, COPD, T2DM, end-
stage renal diseases, and HIV [88].
The combination of a high body fat and a low skeletal muscle
mass seems particularly detrimental for health. Individuals with
this type of body composition have a higher risk of functional
impairment and all-cause mortality compared to those with high
body fat and normal skeletal muscle mass [89,90]. Interestingly, it
has been reported that muscle mass is only a minor determinant of
muscle strength, supported by the fact that, with aging, there is a
more rapid loss of muscle strength than muscle mass, likely related
to changes in neurological function and intrinsic properties of
skeletal muscle [91].
Peripheral muscle strength adjusted for fat-free mass was
shown to be at least 6% lower in obese than normal-weight in-
dividuals [92], A few studies have evaluated the link of muscle
strength and mortality in individuals with a BMI � 25 kg/m2,
without taking into account fat-free mass [93,94]. They found the
worst prognosis in individuals with the lowest tertile of handgrip
strength, as compared to individuals with normal weight and high
handgrip strength. Consequently, poor muscle strength negatively
affects outcome in obese people but the impact of fat-free mass on
this relationship needs to be clariﬁed.
A high CRF has been related with lower CV and all-cause mor-
tality. A meta-analysis reported that a 1 km/h increased maximal
running speed decreases all-cause mortality by 13% and risk of CV
diseases by 15% [95]. Although the beneﬁcial impact of high CRF
may be partly related to a lower total and visceral body fat, several
studies have found that CRF is a more important predictor of
outcome than body composition [96,97]. A cohort study reported
that mortality was similar in obese ﬁt individuals compared with
normal-weight ﬁt individuals, but 6 times higher in overweight
unﬁt individuals and 9 times higher in normal-weight unﬁt in-
dividuals [98]. Furthermore, individuals with abdominal adiposity,
either ﬁt or unﬁt, had an increased risk of mortality compared to ﬁt
individuals without abdominal adiposity [98]. These ﬁndings
indicate that a good CRF is an essential component of health-
related physical ﬁtness.
In conclusion, health-related ﬁtness predicts outcome of obese
people, although the respective contribution of each component
remains to be untangled. Obese people should thrive to a high
muscle mass and strength and low visceral adiposity, a high CRF
and a high ﬂexibility.
2.11. Obesity-related joint diseases
Obesity can in some cases raise the risk for certain types of
arthritis; but in all cases, obesity worsens arthritis. One in ﬁve
Americans has been diagnosed with arthritis, but according to the
Centers for Disease Control and Prevention, that number is higher
among obese people and affects 1 out of 3 of them. The odds of
arthritis and osteoarthritis (OA) are up to 7 times higher in obese
people, compared with underweight or normal weight individuals
[99].
Table 3
Components of health-related ﬁtness (adapted from Ref. [230]).
Component Methods of assessment
Body composition Body mass index, skinfold thickness, bioimpedance
analysis, hydrodensitometry, dual-energy X-ray
absorptiometry, computed tomography, magnetic
resonance imaging
Muscular strength One RM,a cable tensiometry, force platforms,
dynamometry
Muscular endurance Repetitions of lifts at a ﬁxed percentage of RM,a of
push-ups or abdominal curls, isokinetic
dynamometry…
Cardio- respiratory
ﬁtness
Peak oxygen consumption (peak VO2)
Flexibility Sit and reach test, goniometry
a RM: repetition maximum ¼ maximum amount of weight lifted at one time.
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8OA is the most common joint disorder, affecting approximately
27 million Americans, with symptoms in the hands, knees, hips,
back, and neck. It is unclear how exactly excess weight inﬂuences
OA, a chronic disease that results from damage to articular cartilage
induced by a complex interplay of genetic, metabolic, biochemical,
and biomechanical factors (Fig. 3). In obesity-related OA, mechan-
ical overload promotes the articular cartilage damage, but adipose
tissue could also contribute to the pathogenesis by stimulating
systemic low-grade inﬂammation and disturbed lipid metabolism
leading to low synthesis/release of functional HDL cholesterol and
high systemic levels of triglycerides, free fatty acids, oxidized LDL,
adipokines and pro-inﬂammatory cytokines. Infrapatellar fat pads
contribute to the high intra-articular levels of adipokines and cy-
tokines [100].
TheWHO initiative on counteracting obesity also accepts OA as a
consequence of obesity [101]. Numerous large studies have shown
a strong association between obesity and radiographic knee OA.
The risk for osteoarthritis of the knee is increased almost fourfold in
obesewomen and ﬁvefold in obesemenwith a BMI of 30e35 kg/m2
compared with lean individuals. In other terms, the risk for oste-
oarthritis of the knee is increased by approximately 15% for each
additional kg/m2 increase in BMI >27 kg/m2 [101].
There seems to be also a relationship between obesity and other
types of OA; however the relationship between obesity and hip OA,
or hand OA, is not as strong, or could not be found at all [102,103]. It
has been suggested that excessive weight may exert a greater
impact on the knee joint because of particular biomechanical fac-
tors, whereas the more stable hip joint is less susceptible [104].
In conclusion, overweight and obesity have been clearly asso-
ciated with OA, which substantially affects mobility and quality of
life of the afﬂicted patients.
2.12. Obesity impact on quality of life
Numerous studies have shown a worse quality of life in obese
patients. The inﬂuence of BMI on health-related quality of life
(HRQoL) occurs mainly in the physical dimension of HRQoL, and in
the overall assessment but not in the mental health category [105].
It has also been observed that the HRQoL of obese patients who opt
for bariatric surgery is worse than that of those who choose a
conventional treatment [106]. Further elements such as chronic
pain, depression, or obstructive sleep apnea, have been associated
with a worse HRQoL in obese patient. Therefore, the identiﬁcation
of these comorbidities is of great importance since they play a
signiﬁcant role on HRQoL [107].
HRQoL improvement is closely related to the amount of weight
loss, regardless of the treatment that the patient has undergone;
either the conventional treatment or bariatric surgery. Further-
more, even if there is some weight regain, as shown in several
studies [106,108], the improvement is sustained. HRQoL improve-
ment is evidenced in the scores of Physical, Psychosocial and Global
dimensions of the Sickness Impact Proﬁle (SIP). If assessed by the
36-Item Short-Form Health Survey (SF-36), it is reﬂected in the
areas of Pain and Physical Functioning, indicating a signiﬁcant
impact on functional status and physical well-being, and in the
perception of the patient's own health. Additionally, in patients
with BMI >30 kg/m2 there is also an improvement of the social
functioning.
2.13. Impact of obesity for chronic diseases
Obesity rates are increasing, not only in the general population,
but also in patients with chronic disease states. This supports the
notion that the overall nutritional condition of patients with a
chronic disease, like in cancer patients, has improved and that any
weight loss because of a health issuewill result in a shift from obese
to overweight rather than from normal weight to underweight
[109]. Chronic diseases are a group of diseases that slowly develop
and need continuous chronic and acute medical care because of
short periods of exacerbation of the symptoms of the disease. Ex-
amples are COPD, chronic heart failure, chronic renal failure, T2DM
and the MetS, but also include cancer survivors or cancer patients
in remission. While obesity is clearly related to the development of
diabetes and the MetS, other pathogenetic associations are
emerging suggesting that obesity may enhance the risk to develop
further organ failures and related chronic diseases.
Fig. 3. Multifactorial association between obesity and osteoarthritis with central roles for loading, dyslipidemia and adipose tissue. Modiﬁed from Ref. [100].
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9How does obesity impact chronic diseases? Obesity can reduce
the mobility and activity of an individual, e.g. by inducing ortho-
pedic problems. On the other hand, obesity can protect people with
chronic diseases from the risk of becoming underweight and losing
muscle mass that will limit rehabilitation and reduce survival. This
view is supported by many studies showing that a moderately high
BMI is related to a lower mortality rate in chronic diseases; the
obesity paradox [90,109e111]. However, this effect could be related
to the fact that obese subjects usually have an increased muscle
mass (Fig. 4) [112]. In other words, if somebody becomes obese, the
muscle mass will increase. Therefore, it is tempting to speculate
that obesity is related to better outcome, because of an increased
muscle mass in the obese and thus muscle mass is related to
outcome. This hypothesis is supported by the observation that in
sarcopenic obesity, the beneﬁt of obesity is not visible anymore or
even turned to a reduced survival. Therefore, identifying and
adequately treating patients with sarcopenic obesity is mandatory
for the outcome.
3. Basic research approaches: fat tissue and beyond
3.1. Skeletal muscle and insulin resistance
Obesity is associated with structural and metabolic changes in
skeletal muscle. Indeed, the accumulation of lipid metabolites and
the consequential dysfunction of glucose utilization in muscle are
early signs of obesity-induced insulin resistance, as the muscle
mitochondrial capacity to oxidize excess fatty acids is limited [113].
Fat inﬁltration is also associated with muscle ﬁber type modiﬁca-
tions, with a decrease in muscle mass and impairments in muscle
function [114], especially in obese older individuals [115]. Inter-
estingly, recent data support the hypothesis that intramyocellular
lipids not only promote defective insulin-stimulated glucose
disposal through insulin resistance, but also have detrimental
consequences on muscle protein turnover through alterations in
signaling pathways mostly involved in stress response [116].
The involvement of adiposity, particularly ectopic lipid deposi-
tion, in the muscle metabolic response to insulin indicates that
muscle protein turnover is strongly affected [117], mostly during
the chronic development of obesity [118], in relation with other
metabolic disorders like lipotoxicity, inﬂammation, or insulin
resistance (Fig. 5). Consequently and beyond metabolic impair-
ments, these obesity-related modiﬁcations of skeletal muscle can
affect mobility, morbidity and quality of life leading in ﬁne to sar-
copenic obesity with advancing age [119].
As sarcopenia is deﬁned as a reduced muscle mass and a
diminished muscle function [2], it is of major importance to better
phenotype muscle functionality in the obese patients in order to
detect those who are prone to early sarcopenic obesity and its
related deleterious effects. Interestingly, recent reports identiﬁed
visceral fat as a possible link between obesity-induced insulin
resistance and sarcopenia [120]. These clinical relationships sug-
gest that the mechanisms of insulin resistance associated with
lipotoxicity should be considered as a potential cause of sarcopenia
in obese patients and a possible therapeutic target.
3.2. Pathophysiology of adipose tissues
Adipose tissue is a dynamic organ that actively contributes to
the regulation of energy balance and nutritional status. Major
breakthroughs in the deﬁnition of this concept include i) the dis-
covery of the endocrine role of adipose tissue to produce complex
patterns of adipokines and cytokines from both adipocytes and
tissue macrophages; ii) the concept of adipose tissue expandability
as a determinant of metabolic responses to positive energy balance;
iii) the concept of differential metabolic and thermogenetic char-
acteristics of adipocytes, with the ‘rediscovery’ of adult brown ad-
ipose tissue.
The discovery of the anorexigenic hormone leptin was probably
the single most relevant ﬁnding to boost researchers' interest in
adipose tissue and its active metabolic function [121]. Since then,
several adipose tissue hormones (adipocytokines or adipokines)
have been described that contribute to regulate intermediate
metabolism, energy metabolism, systemic inﬂammation, vascular
function and hemostasis [121]. The unfavorable obesity-related
pattern of low protective adiponectin with parallel increment of
several proinﬂammatory and pro-atherogenic cytokines is strongly
associated with the MetS [121]. Adipose tissue oxidative stress
could exert a negative metabolic impact also by altering adipokine
production [122]. In clinical studies, associations between plasma
peroxidation markers and low adiponectin have been reported in
both obese and non-obese individuals [122]. Selected nutrients or
nutrition-modulated metabolites, including vitamin D, uric acid
and omega-3 fatty acids, are emerging as mechanistic regulators of
adipose tissue metabolism and endocrine function [123]. Regula-
tion of adipokine production remains an exciting research area
with strong potential clinical impact.
Fig. 4. Relation between BMI and FFMI (representing mainly muscle mass). From Ref.
[112].
Fig. 5. Mechanisms of obesity-related insulin resistance and its links with alterations
of muscle protein metabolism. For explanations see text.
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Adipose tissue expansion through adipocyte differentiation and
proliferation is reported to be preferentially associated with
metabolic beneﬁts [124]. On the other hand, expanded fat mass
through cell hypertrophy without recruitment of newly differen-
tiated cells may lead to adipocyte damage, cell death and ultimately
enhanced inﬂammation through macrophage activation [125].
These mechanisms may contribute to shape metabolic responses in
human obesity. Hormonal and nutritional modulation of adipocyte
differentiation and proliferation remain largely unknown and
deserve future studies.
The management of obesity by increasing body energy dissi-
pation through heat production appears promising. Brown adipo-
cytes have higher thermogenic potential due to enhanced
mitochondrial uncoupling that makes them less efﬁcient ATP pro-
ducers. Contrary to previous beliefs, brown adipose tissue is pre-
served after infancy through adult life in humans [125,126].
‘Browning’ of adipose tissue, i.e. interconversion of metabolically
white into brown adipocytes, has been reported following meta-
bolic stimuli such as cold exposure and physical exercise in
experimental models, but potential nutritional regulation of
adipocyte browning and related changes in energy metabolism
remain virtually unknown.
Visceral adipose tissue accumulation is well known to be asso-
ciated with high risk of obesity-associated metabolic and CV
complications, although underlying mechanisms remain only
partially understood [127]. Factors regulating central adipose tissue
distribution are also incompletely deﬁned, although they include a
negative impact by estrogen and stimulation by cortisol. Genetic,
gender-related factors are also likely but yet poorly deﬁned
contributors.
In conclusion, excess body fat is the deﬁning alteration in
obesity. Altered adipose tissue functions in obesity likely play a key
role in the development of complications.
3.3. Obesity and the gut microbiota
In the last few years, the gut microbiota has been proposed as an
environmental factor that could be implicated in adiposity and
related metabolic diseases. Dysbiosis, deﬁned as changes in gut
microbial composition, localization, and metabolic function, char-
acterizes obese versus lean individuals [128]. Germ free mice,
colonized with the gut microbiota from obese mice or humans,
acquire an obese and/or diabetic phenotype. Those data suggest
that the metabolic characteristics of the obese microbiome can
increase the ability to extract energy from the diet and store this
energy in the adipose tissue. Several hypotheses have been re-
ported to explain the association between dysbiosis and metabolic
disease, including increased energy harvest, changes in host gene
expression, alterations in the gut barrier, and contributing to
inﬂammation and adiposity [129].
Some components of the gut microbiota, as well as metabolites
issued from microbial metabolism of nutrients of host related
components, may play a role in key functions related to adiposity
and metabolic disorders. Among the metabolites produced in the
gut, short-chain fatty acids (SCFA) can be used as energy sources by
the host, but can also act as regulators of energy intake and energy
metabolism [130,131]. The tremendous variety of bile acids present
in the gut reveals the important contribution of the gut microbiota
for the release of steroids able to modulate the gut endocrine
function and beyond, e.g. in the liver or in adipose tissue, once
steroids reach the systemic circulation.
The metabolomic and metagenomic analyses of the gut micro-
biota allowed to explore the panel of bacterial metabolites able to
act on host energy metabolism and to participate to metabolic al-
terations. Some bacterial componentse released independent from
nutrient transformation e may also play a role in obesity and
related metabolic disorders, like the lipopolysaccharides (LPS)
present in gram negative bacteria, peptidoglycans, ﬂagellins, or
bacterial DNA [131e133].
Since dysbiosis has been clearly associated with obesity, there is
a growing interest in evaluating changes in gut microbiota occur-
ring following weight loss, and in developing alternative (‘pro-
biotic’) therapies for weight control and prevention of obesity. The
surgical approaches (gastric bypass, gastrectomy), which are
effective treatments for weight reduction, lead to profound changes
in gut microbiota, in favor, for example, of bacteria prone to
improve the gut barrier function (Akkermansia muciniphila), and to
changes in bacterial phyla involved in energy sparing [128,134].
These observations raise the question whether some alterations of
the gutmicrobiotamay be the consequence rather than the cause of
obesity.
The transfer of the gut microbiota from apparently healthy do-
nors to individuals presenting a MetS allowed to improve insulin
resistance for several weeks, thereby opening the door to novel
approaches in the management of metabolic disorders associated
to obesity [128]. Future dietary advices should also consider the
evolution of the knowledge in the ﬁeld of microbiota-host in-
teractions. Interesting recent papers pointed out how modeling of
metagenomics and metabolomics data could help elaborating a
more personalized nutrition in obese individuals, taking into ac-
count both the characteristics of the diet and the taxonomic/
metabolic activity of the gut microbiota [135]. The administration
of probiotics (live bacteria given orally) or prebiotics have been
proposed as novel strategies to modulate the composition and ac-
tivity of the microbial gut ecology. Several prebiotic dietary ﬁbers
arewell characterized and their administration promotes growth of
beneﬁcial microorganisms such as Biﬁdobacterium species, A.
muciniphila, and Faecalibacterium prausnitzii [132]. These microor-
ganisms are involved in the improvement of key gut functions
including endocrine function, resulting in decreased inﬂammation,
enhanced satiety and improved health. Up to now, the number of
intervention studies exploring new tools (microbiota transfer,
probiotic, prebiotic approaches) in obese or overweight individuals
is still low.
3.4. The gut-liver-axis
Almost all patients with obesity develop liver steatosis, also
named NAFLD, which sometimes proceeds to non-alcoholic stea-
tohepatitis' (NASH), a severe complication of obesity that may lead
to acute liver failure [136,137]. Patients with NASH have an
enhanced risk to develop liver ﬁbrosis and cirrhosis, and even he-
patocellular carcinoma (HCC). About 20% of the obese patients
develop NASH (3) [138], and 5e10% of the NASH patients develop
HCC [139].
NFLD has been recognized now as an early indicator of obesity-
associated pathologies such as insulin resistance, atherogenesis and
myocardial dysfunction [25]. This association suggests that changes
in the liver may not only precede such pathologies often summa-
rized as the MetS, but trigger or at least facilitate metabolic and CV
disorders. This hypothesis is supported by the observation that the
2/3 of obese individuals who develop metabolic diseases almost
always show metabolic liver disease, whereas the 1/3 of obese in-
dividuals not afﬂicted (‘the healthy obese’) show a normal liver
[140,141]. Obviously, the steatosis of the liver, but also of other or-
gans such as skeletal and heart muscle and intestine, primes for
metabolic and CV diseases as well as cardiac arrhythmias like atrial
ﬁbrillation [142]. Although the molecular mechanisms explaining
this association are not fully understood at present, pronounced
NAFLD in the obese can be regarded as an early indicator for
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particular risks such as diabetes, CV diseases and hepatocellular
carcinoma.
In this context, the question raises what causes liver steatosis in
the obese and what are the possible pathophysiological conse-
quences. Particular food such as high-fat diet and sugars, especially
fructose, seem to promote the development of NAFLD. In animal
experiments, it was shown that this triggering effect of particular
food occurs independently of calorie intake suggesting that not
only the energy intake but also food quality determines about
obesity-associated diseases. Evidence from animal experiments
[133,143,144], and to some extent also human studies [145,146],
suggests that translocation of bacterial products such as endotoxin
from the intestine to the liver triggers NAFLD and inﬂammation in
the obese. Whether the above mentioned food induces NAFLD by
causing intestinal barrier impairment and subsequent endotoxin
translocation or also by other mechanisms, is unclear at present. On
the other hand, such experiments strongly suggest that not only the
amount of energy uptake by diet, but also diet composition de-
termines about obesity and obesity-associated diseases. Therefore,
the gut-liver-axis anatomically represented by the portal vein
transporting food components as well as bacterial products from
the intestine to the liver deserves more attention. Intestinal barrier
functions may become a new determinant of obesity risk or
metabolic disease risk and dietetic strategies that address such
mechanisms might affect future therapeutic strategies [58].
3.5. Future research directions
Basic research on obesity relates to several aspects addressed in
the previous chapters. One should not just focus on negative effects
of obesity. There are clear indications that survival beneﬁts from
overweight and obesity, which is likely related to the increase in
muscle mass [90,109,110,147e149]. Therefore, there are character-
istics of overweight and obese subjects like individual body
composition, or genetic and metabolic phenotype, that determine
whether a certain characteristic will have a beneﬁcial or harmful
effect on health and the capacity to cope with a chronic disease. We
clearly have only limited knowledge of the different phenotypes of
overweight and obese subjects to be able to relate this to health.
Besides careful phenotyping of obese subjects, we need to
introduce more advanced analytical approaches. For instance, a
new state-of-the-art stable isotope approach to characterize ki-
netics of substrates in a large number of obese subjects was
introduced. By giving one pulse of a mixture of many stable iso-
topes of amino acids and keto-acids, and taking blood samples at
deﬁned intervals, this technique allows to calculate the plasma and
intracellular appearance and inter-conversions of substrates to
better phenotype obese subjects on a metabolic level. Using other
recently introduced stable isotope methods, the rates of protein
digestion and amino acid absorption after consuming a deﬁned
protein meal can be assessed [150]. By the use of these metabolic
kinetic approaches, together with other methods, we can link these
data to the variation in muscle mass, bone mineral density, muscle
function, quality of life, well-being, neuropsychological function
etc. that will generate new leads to reﬁne and individualize nutri-
tional therapies with optimal protein and amino acid composition
designed to treat the negative effects of the overweight and obesity,
which will positively inﬂuence the outcome of these patients.
4. Screening and assessment
4.1. Basic examinations in obesity
In all patients, a detailed history and examination should
contribute to assess obesity stage and risk level (Table 4). Recent
guideline recommendations [76] have more clearly introduced the
concept of primary care involvement in risk stratiﬁcation, by
explicitly recommending measurement of waist circumference, a
major marker of insulin resistance and its complications. Patients
with high waist circumference should be further tested for altered
blood pressure, blood glucose and lipids, and should be advised to
lose even moderate amounts (<5%) of body weight.
Measurement of sex hormones is indicated in the presence of
clinical alterations, such as clinical hypogonadism and-or erectile
dysfunction inmales or oligo-amenorrhea and hirsutism in females
(Table 4). In selected cases, particularly in those resistant to dietary
weight loss for unclear reasons, energy balance assessment by in-
direct calorimetry can be considered [151]. Indirect calorimetry
may support not only individual dietetic recommendations, but
may also allow a more precise calculation of metabolic equivalents
(MET) in overweight to extremely obese subjects [152].
Bio-electric impedance analysis (BIA) can be used for the
assessment of body composition, especially muscle mass or lean
body mass, if dual X-ray absorptiometry (DXA) is not available.
Although BIA might be less accurate, it is the most suitable means
in a clinical setting because it is simple, inexpensive, noninvasive,
and highly reproducible [153]. In particular, for follow-up analyses,
e.g. during weight loss therapy, BIA seems to be appropriate to
Table 4
Diagnostic means in patients with obesity.
Category Examinationa
Patient's history Weight history
Previous efforts to lose weight
Physical activity
Eating habits, 7-days-food-protocol
Psychosocial performance
Family history
Drug history
Depression scale
Physical examination
and anthropometry
Actual body weight and height
Waist circumference (if BMI < 35 kg/m2)
Blood pressure
Body impedance analysis
Hand grip strength
Ultrasound (liver steatosis? Gallstones?),
elastography, MRI
Calorimetry
Laboratory tests Fasting plasma glucose, HbA1c, 2-h 75-g oral glucose
tolerance
Lipids (triglycerides, total/HDL/LDL cholesterol,
small dense LDL)
Transaminases
Uric acid, creatinine, micro-albuminuria
Complete blood count, ferritin, transferrin
saturation
Micronutrients: vitamins (vitamin D, folic acid, etc.)
calcium, potassium, zinc, selenium, iodine
Somatic hormones (TSH, cortisol)
Sex hormones
Sleep apnea diagnostic Validated questionnaires (e.g. the Epworth Sleepiness
Scale and the Berlin Questionnaire)
Polysomnography (“gold standard” method)
Cardiovascular risk
assessment
Scale scores such as the Framingham Risk Score, the
NCEP ATP III risk assessment or the SCORE scale
Diagnostic criteria for
sarcopenic obesity
Muscle mass measurement (dual X-ray
absorptiometry, DXA, or bio-electric impedance
analysis, BIA)
Calculation of the FFMI (fat-free mass index ¼ fat-free
mass/height2)
Muscle strength and/or function measurement (gait
speed, chair standing test, hand grip measurement)
Muscle power estimation by the Activities of Daily
Living (ADL) score or the Short Physical Performance
Battery (SPPB) instrument
a Examinations printed in italic are recommended only in the presence of clinical
alterations (for details see text).
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assess loss of muscle mass [154]. At least muscle mass and total fat
mass can be measured adequately, whereas measurement of
visceral fat requires DXA or MRI [155]. Moreover, BIA can be helpful
for motivation of obese individuals under weight loss therapy,
because not only to monitor change of weight, but also prognos-
tically relevant improvement of body composition.
4.2. Diagnostic criteria for sarcopenic obesity
There are no commonly accepted criteria for sarcopenic obesity
beyond those for sarcopenia and obesity separately. The ESPEN
endorsed recommendations of the European Working Group on
Sarcopenia in Older Persons [156], as well as the statement from
the ESPEN Special Interests Groups of Cachexia in Chronic Disease
and Nutrition in Geriatrics indicate an algorithm based on loss of
muscle mass and strength and/or function [157].
Muscle mass could be measured by any validated technique,
which in clinical practice would usually involve DXA or BIA. For
body composition measurement in clinical practice DXA might be
most accurate in obese individuals. However, such diagnosis is not
always easily available. There is no clear consensus about normal
ranges for FFMI (fat-free mass index ¼ fat-free mass/height2), and
the uncertainty is even larger for the obese individual, since the
normal ranges might be different from the lean population [158].
For example, reduced muscle mass could be indicated by an
appendicular skeletal muscle mass index <7.26 kg/m2 (men) and
<5.5 kg/m2 (women) [2]. Using the BIA method in a large cohort of
hospital patients, low FFMI and high FMI was associated with a
poor outcome in terms of length of hospital stay compared with
normal FFMI or FMI [159].
Muscle function may be assessed by measuring gait speed or by
the chair standing test (which tests lower extremities) or by eval-
uating muscle strength using the hand grip measurement [160].
Practical diagnostic cut-offs for gait speed are considered to be:
<0.8 m/s (2) or <1.0 m/s (3). Suggested cut-off points for reduced
muscle strength measured by handgrip strength are <20 kg for
women and <30 kg for men (2). Alternatively, muscle power can
estimated by the assessment of the patient autonomy using the
Activities of Daily Living (ADL) score or the Short Physical Perfor-
mance Battery (SPPB) instrument [161].
4.3. Assessment of co-morbidities
Obesity can progressively cause and/or exacerbate a wide
spectrum of co-morbidities, including CV disease, T2DM, hyper-
tension, dyslipidemia, liver dysfunction, respiratory and musculo-
skeletal disorders, sub-fertility, psychosocial problems, cognition,
and certain types of cancer. Current guidelines for the management
of overweight and obesity in adults recommend measuring BMI at
annual visits or more frequently at ‘expert opinion’ level and also
waist circumference (except in patients with BMI> 35 kg/m2) [162].
Blood pressure, fasting plasma glucose and lipids are further rec-
ommended for risk assessment for CVD and DM in this population
[162].
The American Diabetes Association recommends testing to
detect T2DM and prediabetes in asymptomatic overweight or obese
adults, of any age, who have one or more additional risk factors, by
means of HbA1c, fasting plasma glucose or 2-h 75-g oral glucose
tolerance test (grade B) [163]. The Framingham Risk Score, the
NCEP ATP III risk assessment and the SCORE scale may be used to
calculate short-term (10-yr) CV risk. Recently, a new risk equation
representative of different ethnic groups (non-Hispanic whites and
African-American) in the US has been developed [164].
Hepatic function of obese patients may be impaired by the
ectopic fat accumulated in the liver, leading to a spectrum of
abnormalities referred to NAFLD. Liver function blood tests and
image tests may be used to screen the severity of the disease.
Obesity is associated with a range of distinct respiratory conditions
including obstructive sleep apnea, obesity hypoventilation syn-
drome, asthma, and COPD. Screening for obstructive sleep apnea
can be performed through validated questionnaires (e.g. the
Epworth Sleepiness Scale and the Berlin Questionnaire), conﬁr-
mation requires polysomnography which remains the “gold stan-
dard” diagnostic method. In obese patients, the proposed
Edmonton Obesity Staging Systemwhich considers the presence of
co-morbidities may provide a simple framework to aid decision
making in clinical practice [165].
4.4. Micronutrient deﬁciencies
Vitamin deﬁcits assessed by serum or plasma levels occur more
frequently in obese individuals that in the general population. This
has been shown for vitamin D [166], vitamin A [167], and folic acid
[168]. More recent studies in patients with advanced obesity un-
dergoing weight reduction through multidisciplinary conservative
programs or bariatric surgery revealed pre-interventional deﬁcits
mainly of vitamin D, but also of retinol, b-carotene, vitamin B6,
vitamin C, vitamin E, and folic acid [169,170]. Also a number of
minerals such as iron, calcium and iodine, and to a less extent
potassium, magnesium, zinc, and selenium are found at lower
levels in obese compared to lean individuals [169e171]. These de-
ﬁciencies might become even more relevant after intervention, in
particular after mal-absorptive bariatric surgery. Thus, obese in-
dividuals should be examined at least for iron status, calcium/
vitamin D status, and one vegetable-associated micronutrient such
as retinol, b-carotene, or folic acid once a year. Other micro-
nutrients can be assessed in case of clinical complications or in
patients at risk, e.g. pregnant women or patients undergoing sur-
gery. There is no general recommendation suggesting micro-
nutrient supplementation in obese people; however, proven
deﬁcits should be treated either by an adequate diet or supple-
ments [172,173].
5. Preventive strategies against obesity
5.1. Preventive strategies in early life
Since obesity treatment strategies in adults and children remain
unsatisfactory, effective primary prevention is of key priority. Pre-
vention aims at reducing the incidence of overweight and obesity,
i.e. to reduce themanifestation of new cases. The best opportunities
of effective prevention exist prior to entering school age [43].
Obesity was more likely to occur in children who were already
overweight when entering Kindergarten. A German representative
health survey in more than 17,000 children and adolescents
revealed that overweight prevalence increases from 9% among
3e6-year-olds to 15% in 7e10-year-olds, whereas in 14e17-year-
olds it remained similar at 17%. Likewise, the prevalence of obesity
more than doubled from 2.9% at age 3e6 years to 6.4% at 7e10
years, whereas the prevalence at 14e17 years was only slightly
higher with 8.5% [174].
These data suggest that particular opportunities for prevention
strategies exist in early childhood, when dietary and lifestyle
preferences are learned and established, for example with setting
based intervention. Key targets include at least 30 min/day of
playful and fun, vigorous physical activity games at the Kinder-
garten setting, regular consumption of fresh fruit and vegetables,
and water intake while limiting sugared beverages and juices [175].
In a cluster randomized trial, this low cost intervention achieved
sustainable effects on food and drink consumption 18 months after
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the start of the intervention, also in the high risk families with
lower education levels. After one year, the prevalence of overweight
was reduced from 18% in the control group to 13.9% in the inter-
vention group (p ¼ 0.05). An European wide day care intervention
program strategy has been developed and is evaluated with
ﬁnancial support of the European Commission in the ‘ToyBox
project’ [176]. Setting based preventive intervention should be
combined with strategies to reach out and actively involve families,
and efforts targeting environmental conditions, e.g. conditions
encouraging regular physical activity, quality standards of school
meals, and responsible marketing of foods and drinks to children.
Prevention should, however, start even earlier. High birth
weight >4000 g induces a 5fold increased risk of becoming over-
weight by the eighth school grade (4) [175]. Early lifestyle and
nutrition during the ﬁrst about 1000 days of life (270 days of
pregnancy and 2 � 365 days of the ﬁrst two years of life) induces
marked programming effects on long-term health until old age,
including the risk of obesity and associated disorders such as dia-
betes [177,178]. Nutrition in early life modulates cytogenesis,
organogenesis, metabolic and endocrine response, pre- and post-
natal growth trajectories, and epigenetic regulation of gene
expression. Current research on early prevention of obesity focuses
on three key hypotheses of early programming of later obesity and
adiposity. The “Fuel mediated ‘in utero’ hypothesis” stipulates that
intrauterine exposure to excessive fuels (e.g. glucose, fatty acids)
resulting from maternal obesity or diabetes, enhances fetal weight
and fat gain and leads to increased obesity later in life. The
“Accelerated postnatal growth hypothesis” links rapid weight gain
in infancy and early childhood to increased later obesity. The
“Mismatch hypothesis” describes that lowprenatal weight gain and
low birth weight, along with high postnatal weight gain, markedly
increases later disease risk.
Maternal obesity has been linked to increased infant birth
weight and body fat content, increased later obesity risk, and
signiﬁcantly shorter life expectancy of the child (Fig. 6) [179]. Pre-
vention is possible. In the randomized controlled ‘Limit trial’, three
face to face sessions counseling overweight women during preg-
nancy to encourage regular physical activity and to limit intake of
sugars and dietary fat achieved a signiﬁcant reduction of high in-
fant birth weight >4 kg by 19% [180]. Numerous studies also link
abnormal weight gain in infancy and in the second year of life to an
approximately doubled risk of obesity up to adulthood (“Acceler-
ated postnatal growth hypothesis”) [181]. Breastfeeding reduces
the likelihood of both high early weight gain and later obesity [182].
Several meta-analyses of large cohort studies reveal that breast
feeding reduces the risk of later obesity by about 12e24%,
compared to conventional bottle feeds [183e185]. The risk of
formula-feeding can be attenuated by improving the composition
of infant formula. In a large multicenter trial funded by the Euro-
pean Commission, we demonstrated that feeding formulae with a
lesser protein content, more similar to the protein content of hu-
man milk, normalizes early weight gain relative to breastfed in-
fants, and it markedly reduces obesity risk at school age 2.4e2.9
fold [186,187]. Further opportunities exist during the complemen-
tary feeding period by avoiding overfeeding and excessive intakes
of sugar and animal protein.
These data demonstrate the preventive potential that exists very
early in life. Improvements in scientiﬁc and technical expertise on
placental biology, epigenetics, and metabolomics provide great
opportunities for enhancing our understanding of the relation be-
tween early life nutrition and later adiposity at the cellular and
molecular level, which should help reﬁning and improving effective
preventive strategies.
5.2. Preventive strategies in adults
The development of obesity (as well as maintaining a new body
weight after an initial successful body-weight loss) is caused by a
combination of individual, environmental, biological and genetic
factors, and, therefore, no single intervention can reasonably be
expected to have a substantial impact on obesity rates. Chronic
overfeeding, sedentary lifestyle and low physical activity along
with shorter sleep duration seem to be major factors leading to
obesity.
Prevention of overweight and obesity requires a systems-level
approach that includes consistent and integrated messages for all
age groups (children, adolescents and adults) [188]. Interventions
should integrate behavioral and environmental approaches that
focus both on dietary intake (nutrition education, dietary coun-
seling) and on physical activity promotion. Small but consistent
changes in lifestyle seem to facilitate best a long-termmaintenance
of the lower body weight.
Consistent self-weighing may help individuals maintaining
their lower weight by allowing them to recognize body weight
changes early enough to adjust behavioral changes [189,190].
Additionally, those who weight daily also report a greater adoption
of diet and exercise behaviors, whereas decreasing self-weighing
frequency seems to be associated with a greater weight gain [189].
Massmedia campaignse in combinationwith other strategiese
could offer a promising means of reaching target populations with
obesity prevention messages. However, careful pre-testing of these
types of ads is needed to ensure avoidance of any unintended
negative impacts (e.g. stigmatization of individuals and increased
levels of body dissatisfaction and/or eating-disordered behavior)
[191]. In an effort to ﬁnd additional ways to promote more healthy
choices, additional taxation for less healthy foods has come into
consideration in various western countries. Such a taxation is
proposed as a mechanism to reduce consumption of energy-dense
food and hence reduce rates of obesity and overweight in the
community [192].
In diets targeting to prevent and treat obesity by manipulating
energy content, macronutrient distribution are commonly set at
15% protein, <30% lipids, and 50e55% carbohydrates, with in-
creases in ﬁber favored [193]. This recommendation may be
effective for decreasing energy density and promoting weight loss
in the short term; however, a low level of satiety could lead to a low
adherence over longer periods. Absolute protein intake seems to be
more important e during weight loss and weight maintenance e
than the percentage of diet's protein. Given then high satiety level
of protein, this might lead to a reduction in food intake under ad
libitum conditions, resulting in successful weight loss and an
increased chance of maintaining the new bodyweight [194].
Fig. 6. Key hypotheses for pre-and postnatal modulation of later risk of obesity and
related disorders. Modiﬁed from Ref. [179].
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An alternative approach to calorie restriction is to lower the
diet's fat content. However, fat-restricted diets have no advantage
compared to calorie-restricted diets in general regarding long-term
weight loss in overweight or obese people [195]. Nevertheless, diets
higher in total fat seem to be associated with higher body weight,
BMI, and waist circumference [196].
Dietary sugars might promote weight gain by increasing energy
consumption and promoting hunger [197]. Therefore, reduction of
sugar intake is an important component of any strategy to avoid
overweight and obesity. In particular, a decrease in the consump-
tion of sugar-sweetened beverages leads to a reduced prevalence of
obesity and related diseases [198,199]. Recent data do not support a
beneﬁcial effect of dairy consumption for weight loss in long-term
studies or studies without energy restriction [200,201].
Low glycemic index or low glycemic load diets might promote
both weight gain prevention and weight loss maintenance in
comparison to other diets. Lowering the glycemic load of the diet
appears to be an effective method that can be easily incorporated
into a person's lifestyle [202]. However, with regards to long term
effects, low glycemic index diets did not show consistent effects on
weight regain after 12 months [194].
In general a healthy diet regime with a regular food intake
divided into 3 to 6 portions and based on the principles of the
Mediterranean diet, combined with continuous physical activity,
can help reducing and maintaining an individual's body weight
(Table 5).
6. Multidisciplinary management of obesity
6.1. Weight reduction and maintenance by diet and lifestyle
intervention
Lifestylemodiﬁcationwith hypocaloric diet and physical activity
are the cornerstones of treating overweight and obesity, as well as
insulin resistance and T2DM. Optimal nutritional support of the
obese and diabetic patient eating orally or needing artiﬁcial
nutrition remains largely to be deﬁned, particularly in the presence
of nutritional deﬁciencies and loss of lean body mass.
Non-surgical obesity therapy comprises weight reduction and
weight maintenance therapy. Weight reduction therapy is always a
time-limited effort that might include a somewhat unbalanced diet
in order to achieve substantial weight reduction. This requires di-
etetic regimen, but also physical exercise and other lifestyle actions,
including behavioral education. All successful weight reduction
therapy needs a subsequent weight maintenance strategy, because
otherwise, weight regain must be expected independently of the
means of weight reduction. The risk of weight regain is larger after
weight loss by conservative means than after bariatric surgery.
The principles of weight reduction and weight maintenance
therapy are quite different. Weight maintenance therapy is a non-
invasive, long-term strategy which resembles to a large extent
preventive strategies against obesity. In the weight reduction
phase, a negative energy balance is required, whereas in the weight
maintenance phase, the energy balance should be even. To achieve
a negative energy balance, calorie saving is mandatory, while dur-
ing the long-lasting maintenance phase, food composition and food
quality becomes more relevant.
Most obesity guidelines recommend weight reduction therapy
in patients with a BMI > 30 kg/m2. Some guidelines indicate even
lower BMI cut-offs (>25 kg/m2) for the initiation of therapy
depending on the presence of metabolic or other co-morbidities or
high psychological strain [162,203e205]. The goal of obesity ther-
apy is a safe and sustained reduction of bodyweight in combination
with a reduced risk for co-morbidities, reduced mortality and
disability, and an improved quality of life.
To achieve a negative energy balance, different approaches need
to be considered: (i) increase of physical activity by exercise or
‘non-exercise-activity thermogenesis’ (NEAT); (ii) low-calorie-diet
while avoiding satiable, energy-dense food; (iii) professional
behavioral therapy including personal coaching and social changes,
and (iv) motivational strategies supporting adherence and accep-
tance. In adults, low-calorie-diet is initially the most important
event, which can be made more effective by using so-called ‘for-
mula diet’ for a limited time (800e1200 kcal/day usually up to 12
weeks). Increase of physical activity has usually limited effects at
therapy start, because most obese individuals lack ﬁtness and
might have limitations such as joint disease. However, in the course
of therapy, the ability to perform exercise usually increases, both
because of better motivation and better mobility once weight
reduction is achieved.
Systematic reviews of RCT showed that the combination of
physical activity, dietetic means and behavioral therapy is more
effective than only one of these components [206e208]. The
combined approach results in an average weight loss of up to 10 kg,
whereas the effects of single components are usually restricted to
5 kg at best. If more than 10 kg (or 10% of initial body weight)
should be reduced, either multidisciplinary conservative inter-
vention programs over at least 6 months using formula diet in the
initial phase or bariatric surgery (if multidisciplinary programs
were not sufﬁciently effective) should be recommended (Table 6).
Nutritional therapy of obesity can be based on fat- and/or
carbohydrate-reduced diets with an energy intake reduction by at
least 500 kcal/day. The type of diet seems to play a minor role in the
phase of weight reduction. In contrast to previous recommenda-
tions, low-carb diets are not inferior compared to low-fat diets
[209]. Physical activity (aim: 150 min/week) in addition to
nutritional therapy leads to a higher loss of body fat, preservation
or increase of muscle mass and improved muscle strength and CRF
compared with dietetic energy restriction alone [210]. Like in non-
Table 5
Recommendations for prevention of overweight/obesity.
Follow a healthy
eating plan
Make healthy food choices, keep your and your family's
calorie needs in mind, and focus on the balance of
energy
Focus on portion
size
Watch the portion sizes in fast food and other
restaurants. Cutting back on portion size will help
balance energy intake
Be active Find activities that you enjoy (approx. ½e1 h/day)
Reduce screen time Limit the use of TVs, computers, DVDs, and videogames
because they limit time for physical activity (<2 h/
d screen time)
Keep track Keep track of your weight, body mass index, and waist
circumference.
Exercise regularly Get 2,5e5 h/week of moderate-intensity activity to
prevent weight gain. Moderately intense physical
activities include fast walking and swimming.
Follow a healthy
eating plan
Focus on low-calorie, nutrient-dense foods, such as
fruits, vegetables and whole grains. Avoid saturated fat
and limit sweets and alcohol.
Be consistent Adhere to your healthy-weight plan asmuch as possible
increases chances of long-term success.
Limit these foods
and drinks
 Sugar-sweetened beverages (soda, fruit drinks, sports
drinks)
 Fruit juice (no more than a small amount per day)
 Reﬁned grains (white bread, white rice, white pasta)
and sweets
 Potatoes (baked or fried)
 Red meat (beef, pork, lamb) and processed meats
(salami, ham, bacon, sausage)
 Other highly processed foods, such as fast food
Avoid overeating  Eat breakfast
 Choose small portions and eat slowly
 Eat at home.
 Eat mindfully
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obese individuals, physical activity should combine at least
endurance and resistance exercise, but likely also include ﬂexibility
and balance exercises as recommended by expert societies
(Table 7). Patients with BMI >35 kg/m2 should preferentially
perform activities avoiding high joint strain. Behavioral therapy is
also mandatory for successful weight loss and should include reg-
ular self-assessments of food intake, physical activity and weight
control (�1�/week) [162]. Both cognitive and motivational strate-
gies should be considered.
Multidisciplinary conservative intervention programs that cover
all these therapeutic strategies are presently the most effective
conservative weight reduction means. They require surveillance by
a physician and clinical evaluations on a regulatory basis [206].
Rapid weight reduction achieved by the use of formal diet is clearly
beneﬁcial as shown many years ago [211] and conﬁrmed recently
[212]. Poor sustainability and a high dropout rate are the twomajor
limitations of presently available conservative weight reduction
programs. Therefore, evidence-based ‘weight maintenance’ follow-
up programs are obligatory to achieve sustainability [213]. If such
well-evaluated programs performed for at least 6 month fail to
reach the goals, bariatric surgery should be considered [214,215].
Relevant criteria for a surgical intervention are summarized in
Table 8. However, 2/3 of the afﬂicted patients have made their
decision prior to any physician's consultation. Future obesity ther-
apy should comprise an interdisciplinary ‘case management’
considering body weight, co-morbidities and patients history by
the different experts.
6.2. Weight reduction by drugs
According to current guidelines, obesity drugs are indicated as
adjuncts to lifestyle intervention in those patients with a BMI
>27 kg/m2 with comorbidity or BMI over 30 kg/m2 [216]. Regarding
efﬁcacy and safety, drugs are deemed effective if they induce a
weight loss�5% of body weight without any signiﬁcant side-effects
after three months of treatment [216]. Historically, safety reasons
have led to the withdrawal of many commercialized drugs due to
CV and central nervous system side effects [217].
The mechanisms of action of the available medications used to
lose weight consist of diminishing intestinal absorption (orlistat),
decreasing appetite or increasing energy expenditure (the
remaining drugs) [217].
In clinical trials obesity medications produce additional weight
loss relative to placebo ranging from approximately 3% of initial
weight for orlistat and lorcaserin, 3e5% for naltrexone/bupropion,
6% for liraglutide, to 9% for maximal dose (15/92 mg) phentermine/
topiramate at one year (Table 9). The proportion of patients
achieving >5% weight loss ranged from 37 to 47% for lorcaserin,
35e73% for orlistat, 48e50% for naltrexone/bupropion, 63% for lir-
aglutide and 67e70% for top-dose phentermine/topiramate. All
these drugs produce greater improvements in many car-
diometabolic risk factors, but no obesity medication has been
shown to reduce CV morbidity or mortality [218].
6.3. Drug avoidance to prevent obesity
Multiplemedications can induceweight gain. In the evaluation of
obese patients, health care professionals should inquire about
Table 6
Effectiveness of different weight reduction means.
Intervention Effecta Literature
Nutritional therapy, physical activity
behavioral therapy as single
interventions
1e2 kg or
RWLb <5%
[1e4]
Nutritional therapy, physical activity
behavioral therapy in combination
over at least 6 month (“multidisciplinary
therapy”)
4e5 kg or
RWL 5e10%
[1e4]
Multidisciplinary therapy and initial
usage of formula diet for 12 weeks
10e30 kg or
RWL 15e26%
[5e7]
Bariatric surgery 20e50 kg or
RWL 20e40%
[15,16]
a Intention-to-treat basis.
b RWL, relative weight loss.
Table 7
Recommendations for physical activity, adapted from Ref. [231].
Aerobic exercise Resistance exercise Flexibility Neuromotor exercisea
Frequency �5 h/wk of moderate exercise or
�3 h/wk of vigorous exercise or
A combination of both
2e3 d/wk �2e3 d/wk �2e3 d/wk
Intensity Moderate and/or vigorous intensity To improve strength (100% ¼ 1 RMb):
- Novice: 60e70%
- Experienced exercisers: � 80%
- Older and previously inactive
individuals: 40e50%
To improve muscular endurance: < 50%
Stretching until feeling tightness Not determined
Duration 150 min/wk with moderate intensityc
or 75 min/wk with vigorous intensityc
or an equivalent combination of both
<20 min in previously inactive
individuals
e - Most adults: static stretch for 10e30 s
- Older adults static stretch for 30e60 s
60 s of total stretching per exercise
�20e30 min/d
Type Involvement of the major muscle
groups, continuous, rhythmic
Major muscle groups Each major muscle-tendon unit Exercises for training
balance, coordination,
agility and gait
Pattern One session or multiple sessions with
bouts of �10 min
To improve strength:
8e12 repetitions, 2e4 sets; To improve
endurance: 15e20 repetitions, 1e2
sets, Rest between sets: 2e3 min
2e4 repetitions in warmed-up muscles Not determined
Progression Gradual increase of duration, frequency
and/or intensity
Gradual increase of resistance and/or
repetitions and/or frequency
Not determined Not determined
a Older individuals.
b RM: one repetition maximum or maximum weight a person can lift in a single repetition.
c Moderate intensity: 3e6 metabolic equivalents (examples: brisk walking, yoga, doubles tennis, golf); vigorous intensity: > 6 metabolic equivalents (examples: running,
hiking uphill, cycling > 16 km/h, singles tennis).
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medications theymay be receiving, obtained either over-the counter
or byprescription.When considering prescription of drugs known to
be associated with weight gain, prescribers should balance its pos-
itive effects versus the risk of causing obesity [216,219e221].
It is important to be familiar with the potential mechanisms of
drugs causing weight gain. This information will help to identify
alternative medications that result in neutral or negative weight
outcomes. In case there are no feasible alternatives, prescribers
should anticipate the adverse effect of promoting obesity, recom-
mend the lowest effective dose and emphasize lifestyle in-
terventions that could prevent weight increase.
The main therapeutic groups that include drugs with potential
risk of obesity are psychotropics, antihypertensives, antidiabetics,
steroid hormones, protease inhibitors, and antihistamines
(Table 10). The difference betweendrugs promotingweight increase
and alternative drugs that are neutral or decrease weight, usually
ranges from one to ﬁve kg of body weight after being administered
for 3e6 months. Therefore, the consequences regarding the devel-
opment of obesity are modest, but not neglectable.
Apart from drugs, there are other environmental chemicals
that may inﬂuence body weight. After absorption, endocrine
disruptors imitate the effect of hormones. These substances are
found in pesticides (tributylin, TBT), ﬂame retardants (poly-
brominated diphenyl ether, PBDE), plasticizers (bisphenol A, BPA),
non-stick coatings (perﬂuoroalkyl sulfonate and perﬂuorooctanoic
acid, PFOA), and organochloride containing compounds (dichlor-
odiphenyltrichloroethane, DDT). This is a relatively new research
area and further investigation is needed for understanding their
role in the current increase in the prevalence of obesity.
6.4. Weight reduction by surgical intervention
Due to its well documented effects in terms of not only sus-
tained weight loss, but also on obesity-associated morbidity and
mortality over time, bariatric surgery is today an established and
integral part of treating morbid obesity. The estimated number of
bariatric surgical procedures performed worldwide increased from
146,000 to 340,000 between 2003 and 2011, the most frequent
techniques being Roux-en Y gastric bypass and sleeve gastrectomy
which together constitute approximately 75% of all procedures
performed [222].
Indications for surgery might vary between and within coun-
tries. In most recommendations and guidelines indications for
surgery include a BMI >40 kg/m2, or >35 kg/m2 in the presence of
obesity-associated comorbidities expected to improve after weight
loss, provided that appropriate non-surgical therapy did not reach
the goals. Moreover, expected compliance with postoperative di-
etary instructions and medical follow-up should be required. Most
important contraindications include medical conditions that make
the expected beneﬁts unlikely to outweigh the risks associated
with the procedure, alcohol or drug abuse/dependence and un-
stable psychiatric disorders including severe eating disorders.
While unsatisfactory weight loss and/or weight regain over time
is seen in a limited number of patients after bariatric surgery, a
Table 8
Relevant criteria in favor or against bariatric surgery for obesity therapy.a
Criteria in favor of bariatric surgery Criteria against bariatric surgery
No or limited success of an adequate non-surgical therapy such as a validated
multidisciplinary therapy program over 6e12 months based on realistic cut-offs
(e.g. <15% relative weight loss or remaining BMI >40 kg/m2)
An adequate non-surgical therapy such as a validated multidisciplinary therapy
program over 6e12 months has not been performed yet
No sustained success of a adequate non-surgical therapy (e.g. return to initial body
weight one year after completion of the weight loss program)
Adequate follow-up care cannot be guaranteed
An adequate non-surgical therapy program cannot be performed (e.g. because of
immobility)
Severe eating disorder (validated by an psychologist), debility and other
relevant restraints
Success of an adequate non-surgical therapy program cannot be expected (e.g.
because of very high insulin requirements >300 IU/day)
Patient not motivated for a surgical intervention
a Lower-ranking criteria for/against bariatric surgery are the initial BMI, the presence of co-morbidities, particular drug therapies, putative ‘urgency’ (e.g. prior to joint
replacement surgery or cardiac surgery), and costs.
Table 9
Drugs currently approved for weight reduction.
Drug Dosage Mechanism of action Efﬁcacya Status Side effects
Phentermine 30e37.5 mg/d Norepinephrine-
releasing agent
3.6 kg; 2e24 wk Approved in 1960s for STU
(3 mo)
Headache, elevated BP, elevated HR,
insomnia, dry mouth, anxiety, constipation
Diethylpropion 75 mg/d Norepinephrine-
releasing agent
3 kg; 6e52 wk FDA approved in 1960s for STU
(3 mo)
Headache, elevated BP, elevated HR,
insomnia, dry mouth, anxiety, constipation
Orlistat 120 mg TID Pancreatic and gastric
lipase inhibitor
2.9e3.4 kg,
2.9e3.4%; 1 y
FDA approved in 1999 for
CWM, EMA approved in 1998
Decreased absorption of fat-soluble vitamins,
steatorrhea, oily spotting, fecal incontinence,
liver failure (rare)
Orlistat over-the-
counter
60e120 mg TID Pancreatic and gastric
lipase inhibitor
2.9e3.4 kg,
2.9e3.4%; 1 y
FDA approved in 2007 for CWM Malabsorption, fecal incontinence, liver
failure (rare)
Lorcaserin 10 mg BID 5HT2c receptor agonist 3.6 kg, 3.6%; 1 y FDA approved in 2012 for CWM Headache, nausea, dry mouth, dizziness,
fatigue, constipation
Phentermine (P)/
Topiramate (T)
7.5e15 mg/d (P),
46e92 mg/d (T)
GABA receptor
modulation (T) plus
Norepinephrine-
releasing agent
6.6e8.6 kg,
6.6e8.6%; 1 y
FDA approved in 2012 for CWM Insomnia, dry mouth, dizziness, constipation,
paresthesia,, dysgeusia
Naltrexone (N)/
Bupropion (B)
32 mg/d (N), 360
mg/d (B)
Catecholamines reuptake
inhibitor (B)opioid
antagonist (N)
4.8%; 1 y FDA approved in 2014 for
CWM, EMA approved on 2015
Nausea, constipation, headache, vomiting,
dizziness
Liraglutide 3.0 mg injectable GLP-1 agonist 5.8 kg, 6%; 1 y FDA approved in 2014 for
CWM, EMA approved in 2015
Nausea, vomiting, pancreatitis
a Weight loss above diet alone, mean weight loss in % or kg; duration of trials; Abbreviations: STU, short-term use; CWM, chronic weight management; BP, blood pressure;
EMA, European Medicines Agency; FDA, Food and Drug Administration; HR, heart rate; BID: twice daily; TID: three times daily.
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sustained weight loss in the range of 20e30% of total body weight
in usually reported in most series [215]. For many patients, loss of
weight per se might be the most important expected result
following bariatric surgery. However, from a health perspective the
beneﬁcial effects on comorbidities such as T2DM, CV disease and
kidney function are considered as more relevant. Meta analyses as
well as RCT's demonstrate that in patients with T2DM, bariatric
surgery is superior compared to conventional medical treatment in
terms of weight loss, improvement of HbA1c and fasting plasma
glucose as well as diabetes remission [223,224]. The precise
mechanisms by which bariatric surgery improves or “cures” T2DM
are not fully deﬁned. Although recurrence of T2DM is seen in up to
40% of patients in long-term follow up, glucose control is still
improved and risk of macrovascular complications reduced
compared to medical treated controls [225,226].
In studies with long-term follow up, such as the Swedish SOS
study [215], bariatric surgery was associated with a reduced CV
mortality and morbidity by about 50% over time compared to
controls matched for initial BMI and age. Cardiac function was also
improved up to 3 years after surgery [227]. Bariatric surgery might
also improve kidney damage as well as kidney function in patients
with CKD. Mingrone et al. showed in a prospective study that
kidney function as measured by GFR was preserved in comparison
to the progressive deterioration in both kidney damage and kidney
function in a matched cohort of obese patients receiving best
medical care without surgery [228]. After bariatric surgery, QoL
scores at one year are improved for physical as well as mental
domains, with effects lasting up to ten years postoperatively in both
males and females [229]. The improvement has been reported to be
related to degree of weight loss and might differ between various
surgical techniques [229].
It should be acknowledged that although bariatric surgery re-
sults in long-lasting beneﬁcial effects on obesity and comorbidities,
it represents a major abdominal surgical procedure with risk of
serious complications such as anastomotic leaks, bleeding, throm-
boembolism, and infection. Althoughmorbidity andmortality rates
are usually low, patient selection as well as preoperative medical
assessment is crucial in order to further improve results after bar-
iatric surgery. In particular, to identify the patients that are likely to
beneﬁt the most from surgery constitutes an important challenge
in the future. A multidisciplinary team should collaborate in the
pre-as well as postoperative setting with emphasis on information
and medical assessment. Risk factors for poor postoperative
outcome such as undetected hypertension, cardiac disease, sub-
optimal glucose control or sleep apnea should be identiﬁed and
controlled/optimized prior to surgery. Bariatric surgical patients
should be submitted to life-long follow up programs in order to
enable detection of complications such as macro- or micronutrient
deﬁciencies or unsatisfactory weight loss. Ultimately, the outcome
after bariatric surgery in terms of sustained weight loss and the
resolution of comorbidities is dependent on the patient's strict
adherence to a life-long follow up program.
7. Outlook
7.1. Rationale and aims of the ESPEN approach to manage obesity
This paper shows the widespread implications of obesity
affecting almost all medical disciplines. The WHO has recognized
that obesity is the largest global chronic health problem in adults.
Consequently, there is strong interest in studying the myriad of
aspects related to obesity, with basic researchers and practitioners
of all sorts and allied health care professions integrated in scientiﬁc
and clinical societies such as ESPEN devoted to this metabolic
disease.
The role of nutrition in the management of obesity should be
emphasized, beyond design and prescription of low-calorie dietary
treatment. This includes nutritional strategies to maintain body
Table 10
Medications associated with weight gain and alternative drugs.
Therapeutic group Drugs promoting weight gain Alternative Drugs Comments
Antidepressants Paroxetine
Mirtazapine
Amitriptyline
Escitalopram
Lithium
Fluoxetine
Sertraline
Citalopram
Escitalopram
Bupropion
Venlafaxine
Fluoxetine and Bupropion more consistently cause weight loss
Antipsychotics Olanzapine
Quetiapine
Risperidone
Perphenazine
Ziprasidone
Aripiprazole
Haloperidol
Alternative drugs produce less weight gain
Antihypertensives b-blockers
w/o a vasodilating component
(Atenolol, Metoprolol, Propranolol)
ACE inhibitors
ARB blockers
Calcium channel blockers
Antidiabetics Sulfonylureas
Glitinides
Thiazolidinediones
Insulin
Metformin
GLP 1agonists
Pramlintide
DPP-4 inhibitors
SGLT-2 inhibitors
a-glucosidase inhibitors
Weight sparing diabetes medications do not cause hypoglycemia and do
not need adjustment for physical exercise. They can be preferred for
T2DM patients requiring insulin
Basal Insulin is associated to less weight gain that prandial ultrarapid or
biphasic insulin
Steroid hormones Prednisone
Prednisolone
Nonsteroidal anti-inﬂammatory
drugs
Contraceptive Drugs Oral contraceptives Injectable contraceptives Conﬂicting results. Limited evidence of weight gain when using
progestin-only contraceptives.
Antiepileptic Drugs Valproic acid Gabapentin
Carbamazepine
1) Felbamate Topiramate
Zonisamide
2) Lamotrigine
Levetiracetam Phenytoin
Alternative drugs may cause weight loss (1) or weight neutral (2)
Antiretroviral Drugs Protease Inhibitors Frequent weight gain, increased deposition of visceral adipose tissue
and lipodystrophy
Abbreviations: ACE, angiotensin-converting enzyme; ARB: angiotensin receptor blockers; DPP-4, Dipeptidyl peptidase IV; GLP-1, glucagon-like peptide-1; SGLT, sodium-
glucose-linked transporter.
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composition and muscle mass and to manage selected deﬁciencies.
In addition, nutritional care represents an important tool to opti-
mize outcome by modulating metabolism and function in many
obesity-associated health conditions, thereby becoming an impor-
tant means to foster multidisciplinarity in this ﬁeld.
7.2. Collaboration between ESPEN and other societies and
initiatives
There are numerous European and international associations
dedicated to the study and management of obesity from different
perspectives. Three examples will be presented in brief. “World
Obesity” is a federation of national obesity associations from over
50 countries around the world, the strength of which lies in uniting
and connecting professionals through international congress
events and the SCOPE online obesity education facility. The “Eu-
ropean Association for the Study of Obesity” (EASO) is a member-
ship association comprising 31 national association members,
which represent more than 4000 individuals across Europe. The
“International Federation for the Surgery of Obesity and Metabolic
Disorders” (IFSO), formed in 1995, is a federation composed of 58
national associations of bariatric surgeons. These and other soci-
eties listed in Table 11 have produced an impressive amount of
resources available to professionals and patients that describe the
state of the art of the evaluation and treatment of obesity. Rec-
ommendations endorsed by these societies are consistent with
those included in this position paper. ESPEN aims to collaborate
with these institutions and to extent the spectrum of scientiﬁc
societies engaged in obesity by adding an international society
primarily engaged in interdisciplinary nutrition and nutritional
medicine.
Conﬂict of interest
None.
References
[1] Cederholm TAP, Ballmer P, Barazzoni R, Biolo G, Bischoff SC, Holst M, et al.
Diagnostic and procedure related terminology of clinical nutrition e an
ESPEN consensus guideline. Clin Nutr 2016. http://dx.doi.org/10.1016/
j.clnu.2016.09.004. xx, in press.
[2] Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, et al.
Sarcopenia: European consensus on deﬁnition and diagnosis: report of the
European Working Group on sarcopenia in older people. Age Ageing
2010;39:412e23.
[3] Fielding RA, Vellas B, Evans WJ, Bhasin S, Morley JE, Newman AB, et al.
Sarcopenia: an undiagnosed condition in older adults. Current consensus
deﬁnition: prevalence, etiology, and consequences. International working
group on sarcopenia. J Am Med Dir Assoc 2011;12:249e56.
[4] Morley JE, Abbatecola AM, Argiles JM, Baracos V, Bauer J, Bhasin S, et al.
Sarcopenia with limited mobility: an international consensus. J Am Med Dir
Assoc 2011;12:403e9.
[5] Stenholm S, Harris TB, Rantanen T, Visser M, Kritchevsky SB, Ferrucci L.
Sarcopenic obesity: deﬁnition, cause and consequences. Curr Opin Clin Nutr
Metab Care 2008;11:693e700.
[6] Zamboni M, Mazzali G, Fantin F, Rossi A, Di Francesco V. Sarcopenic obesity:
a new category of obesity in the elderly. Nutr Metab Cardiovasc Dis 2008;18:
388e95.
[7] Lissner L, Sjostrom L, Bengtsson C, Bouchard C, Larsson B. The natural history
of obesity in an obese population and associations with metabolic aberra-
tions. Int J Obes Relat Metab Disord 1994;18:441e7.
[8] Sowemimo OA, Yood SM, Courtney J, Moore J, Huang M, Ross R, et al. Natural
history of morbid obesity without surgical intervention. Surg Obes Relat Dis
2007;3:73e7. discussion 7.
[9] Swinburn BA, Sacks G, Hall KD, McPherson K, Finegood DT, Moodie ML, et al.
The global obesity pandemic: shaped by global drivers and local environ-
ments. Lancet 2011;378:804e14.
[10] Hartz AJ, Rimm AA. Natural history of obesity in 6,946 women between 50
and 59 years of age. Am J Public Health 1980;70:385e8.
[11] Barazzoni R, Van Gossum A, Singer P, Bischoff SC. Should ESPEN engage in
facing the obesity challenge? Clin Nutr 2015;34:169e70.
[12] Glass CK, Olefsky JM. Inﬂammation and lipid signaling in the etiology of
insulin resistance. Cell Metab 2012;15:635e45.
[13] Muoio DM, Neufer PD. Lipid-induced mitochondrial stress and insulin action
in muscle. Cell Metab 2012;15:595e605.
[14] Inzucchi SE. Clinical practice. Management of hyperglycemia in the hospital
setting. N Engl J Med 2006;355:1903e11.
[15] Allan CA, McLachlan RI. Androgens and obesity. Curr Opin Endocrinol Dia-
betes Obes 2010;17:224e32.
[16] Legro RS, Arslanian SA, Ehrmann DA, Hoeger KM, Murad MH, Pasquali R,
et al. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine
Society clinical practice guideline. J Clin Endocrinol Metab 2013;98:
4565e92.
[17] Abraham SB, Rubino D, Sinaii N, Ramsey S, Nieman LK. Cortisol, obesity, and
the metabolic syndrome: a cross-sectional study of obese subjects and re-
view of the literature. Obes (Silver Spring) 2013;21:E105e17.
[18] Ouchi N, Parker JL, Lugus JJ, Walsh K. Adipokines in inﬂammation and
metabolic disease. Nat Rev Immunol 2011;11:85e97.
[19] DeMarco VG, Aroor AR, Sowers JR. The pathophysiology of hypertension in
patients with obesity. Nat Rev Endocrinol 2014;10:364e76.
[20] Cernea S, Raz I. Therapy in the early stage: incretins. Diabetes Care
2011;34(Suppl. 2):S264e71.
[21] Delhanty PJ, Neggers SJ, van der Lely AJ. Mechanisms in endocrinology:
ghrelin: the differences between acyl- and des-acyl ghrelin. Eur J Endocrinol
2012;167:601e8.
[22] Ritze Y, Hengelhaupt C, Bardos G, Ernst B, Thurnheer M, D'Haese JG, et al.
Altered intestinal neuroendocrine gene expression in humans with obesity.
Obesity 2015;23:2278e85.
[23] Young RL, Lumsden AL, Keating DJ. Gut serotonin is a regulator of obesity and
metabolism. Gastroenterology 2015;149:253e5.
[24] Jiang C, Xie C, Lv Y, Li J, Krausz KW, Shi J, et al. Intestine-selective farnesoid X
receptor inhibition improves obesity-related metabolic dysfunction. Nat
Commun 2015;6:10166.
[25] Cusi K. Role of obesity and lipotoxicity in the development of nonalcoholic
steatohepatitis: pathophysiology and clinical implications. Gastroenterology
2012;142. 711e25.e6.
[26] Michelotti GA, Machado MV, Diehl AM. NAFLD, NASH and liver cancer. Nat
Rev Gastroenterol Hepatol 2013;10:656e65.
[27] Kethu SR, Banerjee S, Barth BA, Desilets DJ, Kaul V, Pedrosa MC, et al.
Endoluminal bariatric techniques. Gastrointest Endosc 2012;76:1e7.
[28] Wang Y, Wang QJ. The prevalence of prehypertension and hypertension
among US adults according to the New Joint National Committee Guidelines.
Arch Intern Med 2004;164:2126.
[29] Tozawa M, Iseki K, Iseki C, Oshiro S, Ikemiya Y, Takishita S. Inﬂuence of
smoking and obesity on the development of proteinuria. Kidney Int 2002;62:
956e62.
Table 11
Internationally reputed societies for the study of obesity.
Association Web address Based in Guidelines and other resources
World Obesity (Formerly IASO, International
Association for the Study of Obesity)
http://www.
worldobesity.org/
United
Kingdom
http://www.worldobesity.org/resources/
The European Association for the Study of
Obesity
http://easo.org/ United
Kingdom
http://easo.org/education-portal/guidelines/
International Federation for the Surgery of
Obesity (IFSO)
http://www.ifso.com/ Italy http://www.ifso.com/wp-content/themes/ypo-theme/pdfs/obesity-bariatric-
and-metabolic-surgery.pdf
The Obese Society http://www.obesity.org/
home
USA http://www.obesity.org/publications/position-and-policies
Obesity Medical Association (Formerly ASBP,
American Society of Bariatric Physicians)
http://obesitymedicine.
org/
USA http://obesitymedicine.org/obesity-algorithm/
Canadian Obesity Network http://www.
obesitynetwork.ca/
Canada http://www.obesitynetwork.ca/resources-pro
S.C. Bischoff et al. / Clinical Nutrition 36 (2017) 917e938934
19
[30] Navarro-Diaz M, Serra A, Romero R, Bonet J, Bayes B, Homs M, et al. Effect
of drastic weight loss after bariatric surgery on renal parameters in
extremely obese patients: long-term follow-up. J Am Soc Nephrol 2006;17:
S213e7.
[31] Hsu C-y. Body mass index and risk for end-stage renal disease. Ann Intern
Med 2006;144:21.
[32] Mafra D, Lobo JC, Barros AF, Koppe L, Vaziri ND, Fouque D. Role of altered
intestinal microbiota in systemic inﬂammation and cardiovascular disease in
chronic kidney disease. Future Microbiol 2014;9:399e410.
[33] Koppe L, Pelletier CC, Alix PM, Kalbacher E, Fouque D, Soulage CO, et al.
Insulin resistance in chronic kidney disease: new lessons from experimental
models. Nephrol Dial Transplant 2013;29:1666e74.
[34] Barros AF, Borges NA, Ferreira DC, Carmo FL, Rosado AS, Fouque D, et al. Is
there interaction between gut microbial proﬁle and cardiovascular risk in
chronic kidney disease patients? Future Microbiol 2015;10:517e26.
[35] Mafra D, Guebre-Egziabher F, Fouque D. Body mass index, muscle and fat in
chronic kidney disease: questions about survival. Nephrol Dial Transplant
2008;23:2461e6.
[36] Hashimoto Y, Tanaka M, Okada H, Senmaru T, Hamaguchi M, Asano M, et al.
Metabolically healthy obesity and risk of incident CKD. Clin J Am Soc Nephrol
2015;10:578e83.
[37] Fouque D, Kalantar-Zadeh K, Kopple J, Cano N, Chauveau P, Cuppari L, et al.
A proposed nomenclature and diagnostic criteria for proteineenergy
wasting in acute and chronic kidney disease. Kidney Int 2007;73:391e8.
[38] Kovesdy CP, Anderson JE, Kalantar-Zadeh K. Paradoxical association between
body mass index and mortality in men with CKD not yet on dialysis. Am J
Kidney Dis 2007;49:581e91.
[39] Navaneethan SD, Yehnert H, Moustarah F, Schreiber MJ, Schauer PR,
Beddhu S. Weight loss interventions in chronic kidney disease: a systematic
review and meta-analysis. Clin J Am Soc Nephrol 2009;4:10.
[40] Hoogeveen EK, Aalten J, Rothman KJ, Roodnat JI, Mallat MJK, Borm G, et al.
Effect of obesity on the outcome of kidney transplantation: a 20-year follow-
up. Transplantation 2011;91:869e74.
[41] Agostoni C, Braegger C, Decsi T, Kolacek S, Koletzko B, Mihatsch W, et al. Role
of dietary factors and food habits in the development of childhood obesity: a
commentary by the ESPGHAN Committee on Nutrition. J Pediatr Gastro-
enterol Nutr 2011;52:662e9.
[42] Ells LJ, Mead E, Atkinson G, Corpeleijn E, Roberts K, Viner R, et al. Surgery for
the treatment of obesity in children and adolescents. Cochrane Database
Syst Rev 2015;(6). http://dx.doi.org/10.1002/14651858.CD011740. Wiley-
Blackwell.
[43] Cunningham SA, Kramer MR, Narayan KMV. Incidence of childhood obesity
in the United States. N Engl J Med 2014;370:403e11.
[44] Lobstein T, Jackson-Leach R. Estimated burden of paediatric obesity and co-
morbidities in Europe. Part 2. Numbers of children with indicators of
obesity-related disease. Int J Pediatr Obes 2006;1:33e41.
[45] Turck D, Michaelsen KF, Shamir R, Braegger C, Campoy C, Colomb V, et al.
World Health Organization 2006 child growth standards and 2007 growth
reference charts. J Pediatr Gastroenterol Nutr 2013;57:258e64.
[46] Oude Luttikhuis H, Baur L, Jansen H, Shrewsbury VA, O'Malley C, Stolk RP,
et al. Interventions for treating obesity in children. Cochrane Database
Syst Rev 2009;(1). http://dx.doi.org/10.1002/14651858.CD001872.pub2.
CD001872, Wiley-Blackwell.
[47] Boland CL, Harris JB, Harris KB. Pharmacological management of obesity in
pediatric patients. Ann Pharmacother 2014;49:220e32.
[48] Scarborough JE, Bennett KM, Englum BR, Pappas TN, Lagoo-Deenadayalan SA.
The impact of functional dependency on outcomes after complex general
and vascular surgery. Ann Surg 2015;261:432e7.
[49] Global BMIMC. Body-mass index and all-cause mortality: individual-
participant-data meta-analysis of 239 prospective studies in four conti-
nents. Lancet 2016;388:776e86.
[50] Fukuda Y, Yamamoto K, Hirao M, Nishikawa K, Maeda S, Haraguchi N, et al.
Prevalence of malnutrition among gastric cancer patients undergoing gas-
trectomy and optimal preoperative nutritional support for preventing sur-
gical site infections. Ann Surg Oncol 2015;22:778e85.
[51] McDermott FD, Heeney A, Kelly ME, Steele RJ, Carlson GL, Winter DC. Sys-
tematic review of preoperative, intraoperative and postoperative risk factors
for colorectal anastomotic leaks. Br J Surg 2015;102:462e79.
[52] Anderin C, Gustafsson UO, Heijbel N, Thorell A. Weight loss before bariatric
surgery and postoperative complications. Ann Surg 2015;261:909e13.
[53] Carli F, Scheede-Bergdahl C. Prehabilitation to enhance perioperative care.
Anesthesiol Clin 2015;33:17e33.
[54] Mechanick JI, Youdim A, Jones DB, Garvey WT, Hurley DL, McMahon MM,
et al. Clinical practice guidelines for the perioperative nutritional, metabolic,
and nonsurgical support of the bariatric surgery patiente2013 update:
cosponsored by American Association of Clinical Endocrinologists, the
Obesity Society, and American Society for Metabolic & Bariatric Surgery.
Obes (Silver Spring) 2013;21(Suppl. 1):27.
[55] Colquitt JL, Pickett K, Loveman E, Frampton GK. Surgery for weight loss in
adults. Cochrane Database Syst Rev 2014 Aug;8(8). http://dx.doi.org/
10.1002/14651858.CD003641.pub4. CD003641, Wiley-Blackwell.
[56] Schauer DP, Arterburn DE, Livingston EH, Coleman KJ, Sidney S, Fisher D,
et al. Impact of bariatric surgery on life expectancy in severely obese patients
with diabetes. Ann Surg 2015;261:914e9.
[57] Beebe ML, Crowley N. Can hypocaloric, high-protein nutrition support be
used in complicated bariatric patients to promote weight loss? Nutr Clin
Pract 2015;30:522e9.
[58] Bischoff SC, Barbara G, Buurman W, Ockhuizen T, Schulzke J-D, Serino M,
et al. Intestinal permeability e a new target for disease prevention and
therapy. BMC Gastroenterol 2014;14:189.
[59] Ryan DH. Nonsurgical weight loss for extreme obesity in primary care set-
tings. Arch Intern Med 2010;170:146.
[60] Flegal KM, Kit BK, Orpana H, Graubard BI. Association of all-cause mortality
with overweight and obesity using standard body mass index categories: a
systematic review and meta-analysis. J Am Med Assoc 2013;309:71e82.
[61] Oga EA, Eseyin OR. The obesity paradox and heart failure: a systematic re-
view of a decade of evidence. J Obes 2016;2016:9040248.
[62] Biolo G, Cederholm T, Muscaritoli M. Muscle contractile and metabolic
dysfunction is a common feature of sarcopenia of aging and chronic diseases:
from sarcopenic obesity to cachexia. Clin Nutr 2014;33:737e48.
[63] Dufour AB, Hannan MT, Murabito JM, Kiel DP, McLean RR. Sarcopenia deﬁ-
nitions considering body size and fat mass are associated with mobility
limitations: the Framingham Study. J Gerontol A Biol Sci Med Sci 2013;68:
168e74.
[64] Atkins JL, Whincup PH, Morris RW, Lennon LT, Papacosta O,
Wannamethee SG. Sarcopenic obesity and risk of cardiovascular disease and
mortality: a population-based cohort study of older men. J Am Geriatr Soc
2014;62:253e60.
[65] Waters DL, Ward AL, Villareal DT. Weight loss in obese adults 65years and
older: a review of the controversy. Exp Gerontol 2013;48:1054e61.
[66] Druml W. ICU patients: fatter is better? Intensive Care Med 2008;34:1961e3.
[67] McClave SA, Martindale RG, Vanek VW, McCarthy M, Roberts P, Taylor B,
et al. Guidelines for the provision and assessment of nutrition support
therapy in the adult critically ill patient: Society of Critical Care Medicine
(SCCM) and American Society for Parenteral and Enteral Nutrition
(A.S.P.E.N.). J Parenter Enteral Nutr 2009;33:277e316.
[68] Kee AL, Isenring E, Hickman I, Vivanti A. Resting energy expenditure of
morbidly obese patients using indirect calorimetry: a systematic review.
Obes Rev 2012;13:753e65.
[69] Port AM, Apovian C. Metabolic support of the obese intensive care unit pa-
tient: a current perspective. Curr Opin Clin Nutr Metab Care 2010;13:
184e91.
[70] Frankenﬁeld DC, Ashcraft CM, Galvan DA. Prediction of resting metabolic rate
in critically ill patients at the extremes of body mass index. J Parenter Enteral
Nutr 2013;37:361e7.
[71] Choban P, Dickerson R, Malone A, Worthington P, Compher C, American
Society for P, et al. A.S.P.E.N. Clinical guidelines: nutrition support of hos-
pitalized adult patients with obesity. J Parenter Enteral Nutr 2013;37:
714e44.
[72] McClave SA, Kushner R, VanWay 3rd CW, Cave M, DeLegge M, Dibaise J, et al.
Nutrition therapy of the severely obese, critically ill patient: summation of
conclusions and recommendations. J Parenter Enteral Nutr 2011;35:
88Se96S.
[73] Borel AL, Schwebel C, Planquette B, Vesin A, Garrouste-Orgeas M, Adrie C,
et al. Initiation of nutritional support is delayed in critically ill obese patients:
a multicenter cohort study. Am J Clin Nutr 2014;100:859e66.
[74] Harvey SE, Parrott F, Harrison DA, Bear DE, Segaran E, Beale R, et al. Trial of
the route of early nutritional support in critically ill adults. N Engl J Med
2014;371:1673e84.
[75] Teixeira PJ, Carraça EV, Marques MM, Rutter H, Oppert J-M, De
Bourdeaudhuij I, et al. Successful behavior change in obesity interventions in
adults: a systematic review of self-regulation mediators. BMC Med 2015:13.
[76] Jensen MD, Ryan DH, Donato KA, Apovian CM, Ard JD, Comuzzie AG, et al.
Executive summary: guidelines (2013) for the management of overweight
and obesity in adults. Obesity. 2014;22:S5eS39.
[77] Kushner RF, Ryan DH. Assessment and lifestyle management of patients with
obesity. J Am Med Assoc 2014;312:943.
[78] Mather AA, Cox BJ, Enns MW, Sareen J. Associations of obesity with psy-
chiatric disorders and suicidal behaviors in a nationally representative
sample. J Psychosom Res 2009;66:277e85.
[79] Elias MF, Elias PK, Sullivan LM, Wolf PA, D'Agostino RB. Lower cognitive
function in the presence of obesity and hypertension: the Framingham heart
study. Int J Obes Relat Metab Disord 2003;27:260e8.
[80] Nousen EK, Franco JG, Sullivan EL. Unraveling the mechanisms responsible
for the comorbidity between metabolic syndrome and mental health dis-
orders. Neuroendocrinology 2013;98:254e66.
[81] Li Y, Dai Q, Jackson JC, Zhang J. Overweight is associated with decreased
cognitive functioning among school-age children and adolescents. Obesity
2008;16:1809e15.
[82] Osika W, Montgomery SM. Physical control and coordination in childhood
and adult obesity: longitudinal birth cohort study. BMJ 2008;337. a699-a.
[83] Smith E, Hay P, Campbell L, Trollor JN. A review of the association between
obesity and cognitive function across the lifespan: implications for novel
approaches to prevention and treatment. Obes Rev 2011;12:740e55.
[84] Gibson EL. The psychobiology of comfort eating. Behav Pharmacol 2012;23:
442e60.
[85] Miller AA, Spencer SJ. Obesity and neuroinﬂammation: a pathway to
cognitive impairment. Brain Behav Immun 2014;42:10e21.
S.C. Bischoff et al. / Clinical Nutrition 36 (2017) 917e938 935
20
[86] Richard D. Cognitive and autonomic determinants of energy homeostasis in
obesity. Nat Rev Endocrinol 2015;11:489e501.
[87] Ekelund U, Besson H, Luan J, May AM, Sharp SJ, Brage S, et al. Physical activity
and gain in abdominal adiposity and body weight: prospective cohort study
in 288,498 men and women. Am J Clin Nutr 2011;93:826e35.
[88] McAuley PA, Blair SN. Obesity paradoxes. J Sports Sci 2011;29:773e82.
[89] Batsis JA, Mackenzie TA, Barre LK, Lopez-Jimenez F, Bartels SJ. Sarcopenia,
sarcopenic obesity and mortality in older adults: results from the National
Health and Nutrition Examination Survey III. Eur J Clin Nutr 2014;68:
1001e7.
[90] Gonzalez MC, Pastore CA, Orlandi SP, Heymsﬁeld SB. Obesity paradox in
cancer: new insights provided by body composition. Am J Clin Nutr 2014;99:
999e1005.
[91] Clark BC, Manini TM. What is dynapenia? Nutrition 2012;28:495e503.
[92] Hulens M, Vansant G, Lysens R, Claessens AL, Muls E, Brumagne S. Study of
differences in peripheral muscle strength of lean versus obese women: an
allometric approach. Int J Obes Relat Metab Disord 2001;25:676e81.
[93] Ruiz JR, Sui X, Lobelo F, Dc Lee, Morrow JR, Jackson AW, et al. Muscular
strength and adiposity as predictors of adulthood cancer mortality in men.
Cancer Epidemiol Biomarkers Prev 2009;18:1468e76.
[94] Stenholm S, Mehta NK, Elo IT, Heli€ovaara M, Koskinen S, Aromaa A. Obesity
and muscle strength as long-term determinants of all-cause mortalityda 33-
year follow-up of the Mini-Finland Health Examination Survey. Int J Obes
Relat Metab Disord 2013;38:1126e32.
[95] Kodama S. Cardiorespiratory ﬁtness as a quantitative predictor of all-cause
mortality and cardiovascular events in healthy men and women. J Am
Med Assoc 2009;301:2024.
[96] Lavie CJ, Cahalin LP, Chase P, Myers J, Bensimhon D, Peberdy MA, et al.
Impact of cardiorespiratory ﬁtness on the obesity paradox in patients with
heart failure. Mayo Clin Proc 2013;88:251e8.
[97] Lee D-c, Sui X, Church TS, Lavie CJ, Jackson AS, Blair SN. Changes in ﬁtness
and fatness on the development of cardiovascular disease risk factors. J Am
Coll Cardiol 2012;59:665e72.
[98] Goel K, Thomas RJ, Squires RW, Coutinho T, Trejo-Gutierrez JF, Somers VK,
et al. Combined effect of cardiorespiratory ﬁtness and adiposity on mortality
in patients with coronary artery disease. Am Heart J 2011;161:590e7.
[99] Ackerman IN, Osborne RH. Obesity and increased burden of hip and knee
joint disease in Australia: results from a national survey. BMC Musculoskelet
Disord 2012;13:254.
[100] Thijssen E, van Caam A, van der Kraan PM. Obesity and osteoarthritis, more
than just wear and tear: pivotal roles for inﬂamed adipose tissue and dys-
lipidaemia in obesity-induced osteoarthritis. Rheumatology 2014;54:
588e600.
[101] WoolfAD,Breedveld F, KvienTK. Controlling theobesity epidemic is important
for maintaining musculoskeletal health. Ann Rheum Dis 2006;65:1401e2.
[102] Grotle M, Hagen KB, Natvig B, Dahl FA, Kvien TK. Obesity and osteoarthritis
in knee, hip and/or hand: an epidemiological study in the general population
with 10 years follow-up. BMC Musculoskelet Disord 2008;9:132.
[103] Lievense AM. Inﬂuence of obesity on the development of osteoarthritis of the
hip: a systematic review. Rheumatology 2002;41:1155e62.
[104] Sharma L, Chang A. Overweight: advancing our understanding of its impact
on the knee and the hip. Ann Rheum Dis 2006;66:141e2.
[105] Bergner M, Bobbitt RA, Carter WB, Gilson BS. The sickness impact proﬁle:
development and ﬁnal revision of a health status measure. Med Care
1981;19:787e805.
[106] Kolotkin RL, Davidson LE, Crosby RD, Hunt SC, Adams TD. Six-year changes in
health-related quality of life in gastric bypass patients versus obese com-
parison groups. Surg Obes Relat Dis 2012;8:625e33.
[107] Warkentin LM, Das D, Majumdar SR, Johnson JA, Padwal RS. The effect of
weight loss on health-related quality of life: systematic review and meta-
analysis of randomized trials. Obes Rev 2013;15:169e82.
[108] Andersen JR, Aasprang A, Karlsen T-I, Karin Natvig G, Våge V, Kolotkin RL.
Health-related quality of life after bariatric surgery: a systematic review of
prospective long-term studies. Surg Obes Relat Dis 2015;11:466e73.
[109] Zogg CK, Mungo B, Lidor AO, Stem M, Rios Diaz AJ, Haider AH, et al. Inﬂuence
of body mass index on outcomes after major resection for cancer. Surgery
2015;158:472e85.
[110] Karrowni W, Kennedy K, Jones P, Valle J, Abdallah M, Daugherty S, et al.
Obesity paradox among survivors of acute myocardial infarction and its
interaction with time. J Am Coll Cardiol 2015;65:A31.
[111] Robinson MK, Mogensen KM, Casey JD, McKane CK, Moromizato T, Rawn JD,
et al. The relationship among obesity, nutritional status, and mortality in the
critically ill. Crit Care Med 2015;43:87e100.
[112] Franssen FM, Rutten EP, Groenen MT, Vanﬂeteren LE, Wouters EF, Spruit MA.
New reference values for body composition by bioelectrical impedance
analysis in the general population: results from the UK Biobank. J Am Med
Dir Assoc 2014;15. 448 e1e6.
[113] Shulman GI. Ectopic fat in insulin resistance, dyslipidemia, and car-
diometabolic disease. N Engl J Med 2014;371:1131e41.
[114] He J, Watkins S, Kelley DE. Skeletal muscle lipid content and oxidative
enzyme activity in relation to muscle ﬁber type in type 2 diabetes and
obesity. Diabetes 2001;50:817e23.
[115] Delmonico MJ, Harris TB, Visser M, Park SW, Conroy MB, Velasquez-
Mieyer P, et al. Longitudinal study of muscle strength, quality, and adipose
tissue inﬁltration. Am J Clin Nutr 2009;90:1579e85.
[116] Tardif N, Salles J, Guillet C, Tordjman J, Reggio S, Landrier J-F, et al. Muscle
ectopic fat deposition contributes to anabolic resistance in obese sarcopenic
old rats through eIF2a activation. Aging Cell 2014;13:1001e11.
[117] Guillet C, Delcourt I, Rance M, Giraudet C, Walrand S, Bedu M, et al. Changes
in basal and insulin and amino acid response of whole body and skeletal
muscle proteins in obese men. J Clin Endocrinol Metab 2009;94:3044e50.
[118] Masgrau A, Mishellany-Dutour A, Murakami H, Beaufr�ere A-M, Walrand S,
Giraudet C, et al. Time-course changes of muscle protein synthesis associated
with obesity-induced lipotoxicity. J Physiol 2012;590:5199e210.
[119] PradoCMM,Wells JCK, Smith SR, StephanBCM, SiervoM. Sarcopenic obesity: a
critical appraisal of the current evidence. Clin Nutr 2012;31:583e601.
[120] Kim TN, Park MS, Ryu JY, Choi HY, Hong HC, Yoo HJ, et al. Impact of visceral
fat on skeletal muscle mass and vice versa in a prospective cohort study: the
Korean Sarcopenic Obesity Study (KSOS). PLoS One 2014;9:e115407.
[121] Blüher M, Mantzoros CS. From leptin to other adipokines in health and
disease: facts and expectations at the beginning of the 21st century. Meta-
bolism 2015;64:131e45.
[122] Furukawa S, Fujita T, Shimabukuro M, Iwaki M, Yamada Y, Nakajima Y, et al.
Increased oxidative stress in obesity and its impact on metabolic syndrome.
J Clin Invest 2004;114:1752e61.
[123] Wu JHY, Cahill LE, Mozaffarian D. Effect of ﬁsh oil on circulating adiponectin:
a systematic review and meta-analysis of randomized controlled trials. J Clin
Endocrinol Metab 2013;98:2451e9.
[124] Gustafson B, Hedjazifar S, Gogg S, Hammarstedt A, Smith U. Insulin resis-
tance and impaired adipogenesis. Trends Endocrinol Metab 2015;26:
193e200.
[125] Giordano A, Smorlesi A, Frontini A, Barbatelli G, Cinti S. Mechanisms in
endocrinology: white, brown and pink adipocytes: the extraordinary plas-
ticity of the adipose organ. Eur J Endocrinol 2014;170:R159e71.
[126] Cohen P, Spiegelman BM. Brown and beige fat: molecular parts of a ther-
mogenic machine. Diabetes 2015;64:2346e51.
[127] Hocking S, Samocha-Bonet D, Milner K-L, Greenﬁeld JR, Chisholm DJ.
Adiposity and insulin resistance in humans: the role of the different tissue
and cellular lipid depots. Endocr Rev 2013;34:463e500.
[128] Nieuwdorp M, Gilijamse PW, Pai N, Kaplan LM. Role of the microbiome in
energy regulation and metabolism. Gastroenterology 2014;146:1525e33.
[129] Geurts L, Neyrinck AM, Delzenne NM, Knauf C, Cani PD. Gut microbiota
controls adipose tissue expansion, gut barrier and glucose metabolism: novel
insights into molecular targets and interventions using prebiotics. Benef
Microbes 2014;5:3e17.
[130] Bindels LB, Dewulf EM, Delzenne NM. GPR43/FFA2: physiopathological
relevance and therapeutic prospects. Trends Pharmacol Sci 2013;34:226e32.
[131] Tremaroli V, B€ackhed F. Functional interactions between the gut microbiota
and host metabolism. Nature 2012;489:242e9.
[132] Delzenne NM, Cani PD, Everard A, Neyrinck AM, Bindels LB. Gut microor-
ganisms as promising targets for the management of type 2 diabetes. Dia-
betologia 2015;58:2206e17.
[133] Spruss A, Kanuri G, Wagnerberger S, Haub S, Bischoff SC, Bergheim I. Toll-like
receptor 4 is involved in the development of fructose-induced hepatic
steatosis in mice. Hepatology 2009;50:1094e104.
[134] Damms-Machado A, Mitra S, Schollenberger AE, Kramer KM, Meile T,
K€onigsrainer A, et al. Effects of surgical and dietary weight loss therapy for
obesity on gut microbiota composition and nutrient absorption. BioMed Res
Int 2015;2015:1e12.
[135] Shoaie S, Ghaffari P, Kovatcheva-Datchary P, Mardinoglu A, Sen P, Pujos-
Guillot E, et al. Quantifying diet-induced metabolic changes of the human
gut microbiome. Cell Metab 2015;22:320e31.
[136] Marchesini G, Petta S, dale Grave R. Diet, weight loss, and liver health in
NAFLD: pathophysiology, evidence and practice. Hepatology 2016;63:
2032e43. n/a-n/a.
[137] Yeh MM, Brunt EM. Pathological features of fatty liver disease. Gastroen-
terology 2014;147:754e64.
[138] Ota T, Takamura T, Kurita S, Matsuzawa N, Kita Y, Uno M, et al. Insulin
resistance accelerates a dietary rat model of nonalcoholic steatohepatitis.
Gastroenterology 2007;132:282e93.
[139] Seitz HK, Stickel F. Risk factors and mechanisms of hepatocarcinogenesis
with special emphasis on alcohol and oxidative stress. Biol Chem 2006;387:
349e60.
[140] Pischon T, Boeing H, Hoffmann K, Bergmann M, Schulze MB, Overvad K, et al.
General and abdominal adiposity and risk of death in Europe. N Engl J Med
2008;359:2105e20.
[141] Stefan N. Identiﬁcation and characterization of metabolically benign obesity
in humans. Arch Intern Med 2008;168:1609.
[142] Despr�es J-P, Lemieux I. Abdominal obesity and metabolic syndrome. Nature
2006;444:881e7.
[143] Ritze Y, B�ardos G, Claus A, Ehrmann V, Bergheim I, Schwiertz A, et al.
Lactobacillus rhamnosus GG protects against non-alcoholic fatty liver dis-
ease in mice. PLoS One 2014;9:e80169.
[144] Spruss A, Kanuri G, Stahl C, Bischoff SC, Bergheim I. Metformin protects
against the development of fructose-induced steatosis in mice: role of the
intestinal barrier function. Lab Invest 2012;92:1020e32.
[145] Volynets V, Küper MA, Strahl S, Maier IB, Spruss A, Wagnerberger S, et al.
Nutrition, intestinal permeability, and blood ethanol levels are altered in
patients with nonalcoholic fatty liver disease (NAFLD). Dig Dis Sci 2012;57:
1932e41.
S.C. Bischoff et al. / Clinical Nutrition 36 (2017) 917e938936
21
[146] Volynets V, Machann J, Küper MA, Maier IB, Spruss A, K€onigsrainer A, et al.
A moderate weight reduction through dietary intervention decreases he-
patic fat content in patients with non-alcoholic fatty liver disease (NAFLD): a
pilot study. Eur J Nutr 2012;52:527e35.
[147] Casas-Vara A, Santolaria F, Fern�andez-Bereciartúa A, Gonz�alez-Reimers E,
García-Ochoa A, Martínez-Riera A. The obesity paradox in elderly patients
with heart failure: analysis of nutritional status. Nutrition 2012;28:
616e22.
[148] Kalantar-Zadeh K, Streja E, Molnar MZ, Lukowsky LR, Krishnan M,
Kovesdy CP, et al. Mortality prediction by surrogates of body composition: an
examination of the obesity paradox in hemodialysis patients using com-
posite ranking score analysis. Am J Epidemiol 2012;175:793e803.
[149] Wannamethee SG, Shaper AG, Whincup PH, Lennon L, Papacosta O, Sattar N.
The obesity paradox in men with coronary heart disease and heart failure:
the role of muscle mass and leptin. Int J Cardiol 2014;171:49e55.
[150] Engelen MPKJ, Com G, Anderson PJ, Deutz NEP. New stable isotope method
to measure protein digestibility and response to pancreatic enzyme intake in
cystic ﬁbrosis. Clin Nutr 2014;33:1024e32.
[151] Anderson EJ, Sylvia LG, Lynch M, Sonnenberg L, Lee H, Nathan DM. Com-
parison of energy assessment methods in overweight individuals. J Acad
Nutr Diet 2014;114:273e8.
[152] Wilms B, Ernst B, Thurnheer M, Weisser B, Schultes B. Correction factors for
the calculation of metabolic equivalents (MET) in overweight to extremely
obese subjects. Int J Obes Relat Metab Disord 2014;38:1383e7.
[153] Rotella CM. Measurement of body composition as a surrogate evaluation of
energy balance in obese patients. WJM 2015;5:1.
[154] Friedrich AE, Damms-Machado A, Meile T, Scheuing N, Stingel K, Basrai M,
et al. Laparoscopic sleeve gastrectomy compared to a multidisciplinary
weight loss program for obesitydeffects on body composition and protein
status. Obes Surg 2013;23:1957e65.
[155] Pietil€ainen KH, Kaye S, Karmi A, Suojanen L, Rissanen A, Virtanen KA.
Agreement of bioelectrical impedance with dual-energy X-ray absorptiom-
etry and MRI to estimate changes in body fat, skeletal muscle and visceral fat
during a 12-month weight loss intervention. Br J Nutr 2012;109:1910e6.
[156] Cawthon PM, Blackwell TL, Cauley J, Kado DM, Barrett-Connor E, Lee CG,
et al. Evaluation of the usefulness of consensus deﬁnitions of sarcopenia in
older men: results from the observational osteoporotic fractures in men
cohort study. J Am Geriatr Soc 2015;63:2247e59.
[157] Muscaritoli M, Anker SD, Argil�es J, Aversa Z, Bauer JM, Biolo G, et al.
Consensus deﬁnition of sarcopenia, cachexia and pre-cachexia: joint docu-
ment elaborated by Special Interest Groups (SIG) “cachexia-anorexia in
chronic wasting diseases” and “nutrition in geriatrics”. Clin Nutr 2010;29:
154e9.
[158] Bosy-Westphal A, Müller MJ. Identiﬁcation of skeletal muscle mass depletion
across age and BMI groups in health and diseasedthere is need for a uniﬁed
deﬁnition. Int J Obes Relat Metab Disord 2014;39:379e86.
[159] Kyle UG, Pirlich M, Lochs H, Schuetz T, Pichard C. Increased length of hospital
stay in underweight and overweight patients at hospital admission: a
controlled population study. Clin Nutr 2005;24:133e42.
[160] Norman K, Stob€aus N, Gonzalez MC, Schulzke J-D, Pirlich M. Hand grip
strength: outcome predictor and marker of nutritional status. Clin Nutr
2011;30:135e42.
[161] Guralnik JM, Simonsick EM, Ferrucci L, Glynn RJ, Berkman LF, Blazer DG, et al.
A short physical performance battery assessing lower extremity function:
association with self-reported disability and prediction of mortality and
nursing home admission. J Gerontol 1994;49:M85e94.
[162] Jensen MD, Ryan DH, Apovian CM, Ard JD, Comuzzie AG, Donato KA, et al.
2013 AHA/ACC/TOS guideline for the management of overweight and
obesity in adults. Circulation 2013;129:S102e38.
[163] Standards ofmedical care in diabetese2014. Diabetes Care 2014;37(Suppl. 1):
S14e80.
(a) Diagnosis and classiﬁcation of diabetes mellitus. Diabetes Care
2014;37(Suppl. 1):S81e90. Diabetes Care. 2014;37:887.
[164] Goff DC, Lloyd-Jones DM, Bennett G, Coady S, D'Agostino RB, Gibbons R, et al.
2013 ACC/AHA guideline on the assessment of cardiovascular risk. J Am Coll
Cardiol 2014;63:2935e59.
[165] Sharma AM, Kushner RF. A proposed clinical staging system for obesity. Int J
Obes Relat Metab Disord 2009;33:289e95.
[166] Pereira-Santos M, Costa PRF, Assis AMO, Santos CAST, Santos DB. Obesity and
vitamin D deﬁciency: a systematic review and meta-analysis. Obes Rev
2015;16:341e9.
[167] García OP. Effect of vitamin A deﬁciency on the immune response in obesity.
Proc Nutr Soc 2012;71:290e7.
[168] da Silva VR, Hausman DB, Kauwell GPA, Sokolow A, Tackett RL, Rathbun SL,
et al. Obesity affects short-term folate pharmacokinetics in women of
childbearing age. Int J Obes Relat Metab Disord 2013;37:1608e10.
[169] Damms-Machado A, Friedrich A, Kramer KM, Stingel K, Meile T, Küper MA,
et al. Pre- and postoperative nutritional deﬁciencies in obese patients un-
dergoing laparoscopic sleeve gastrectomy. Obes Surg 2012;22:881e9.
[170] Damms-Machado A, Weser G, Bischoff SC. Micronutrient deﬁciency in obese
subjects undergoing low calorie diet. Nutr J 2012;11:34.
[171] Schollenberger AE, Heinze JM, Meile T, Peter A, K€onigsrainer A, Bischoff SC.
Markers of bone metabolism in obese individuals undergoing laparoscopic
sleeve gastrectomy. Obes Surg 2014;25:1439e45.
[172] Soares MJ, Chan She Ping-Delfos W, Ghanbari MH. Calcium and vitamin D for
obesity: a review of randomized controlled trials. Eur J Clin Nutr 2011;65:
994e1004.
[173] Stein J, Stier C, Raab H, Weiner R. Review article: the nutritional and phar-
macological consequences of obesity surgery. Aliment Pharmacol Ther
2014;40:582e609.
[174] Kurth BM, Schaffrath Rosario A. The prevalence of overweight and obese
children and adolescents living in Germany. Results of the German Health
Interview and Examination Survey for Children and Adolescents (KiGGS).
Bundesgesundheitsblatt Gesundheitsforsch Gesundheitsschutz 2007;50:
736e43.
[175] Bayer O, von Kries R, Strauss A, Mitschek C, Toschke AM, Hose A, et al. Short-
and mid-term effects of a setting based prevention program to reduce
obesity risk factors in children: a cluster-randomized trial. Clin Nutr
2009;28:122e8.
[176] Duvinage K, Ibrügger S, Kreichauf S, Wildgruber A, De Craemer M, De
Decker E, et al. Developing the intervention material to increase physical
activity levels of European preschool children: the ToyBox-study. Obes Rev
2014;15:27e39.
[177] Brands B, Demmelmair H, Koletzko B. How growth due to infant nutrition
inﬂuences obesity and later disease risk. Acta Paediatr 2014;103:578e85.
[178] Koletzko B, Brands B, Chourdakis M, Cramer S, Grote V, Hellmuth C, et al. The
power of programming and the EarlyNutrition project: opportunities for
health promotion by nutrition during the ﬁrst thousand days of life and
beyond. Ann Nutr Metab 2014;64:187e96.
[179] Koletzko B, Symonds ME, Olsen SF. Programming research: where are we
and where do we go from here? Am J Clin Nutr 2011;94:2036Se43S.
[180] Dodd JM, Turnbull D, McPhee AJ, Deussen AR, Grivell RM, Yelland LN, et al.
Antenatal lifestyle advice for women who are overweight or obese: LIMIT
randomised trial. BMJ 2014;348. g1285-g.
[181] Koletzko B, Chourdakis M, Grote V, Hellmuth C, Prell C, Rzehak P, et al.
Regulation of early human growth: impact on long-term health. Ann Nutr
Metab 2014;65:101e9.
[182] Koletzko B, von Kries R, Monasterolo RC, Subias JE, Scaglioni S, Giovannini M,
et al. Infant feeding and later obesity risk. Adv Exp Med Biol 2009;646:
15e29. Springer Science þ Business Media.
[183] Arenz S, Rückerl R, Koletzko B, von Kries R. Breast-feeding and childhood
obesityda systematic review. Int J Obes Relat Metab Disord 2004;28:
1247e56.
[184] Horta BL, Loret de Mola C, Victora CG. Long-term consequences of breast-
feeding on cholesterol, obesity, systolic blood pressure and type 2 diabetes: a
systematic review and meta-analysis. Acta Paediatr Suppl 2015;104:30e7.
[185] Yan J, Liu L, Zhu Y, Huang G, Wang P. The association between breastfeeding
and childhood obesity: a meta-analysis. BMC Public Health 2014;14:1267.
[186] Koletzko B, von Kries R, Closa R, Escribano J, Scaglioni S, Giovannini M, et al.
Lower protein in infant formula is associated with lower weight up to age 2
y: a randomized clinical trial. Am J Clin Nutr 2009;89:1836e45.
[187] Weber M, Grote V, Closa-Monasterolo R, Escribano J, Langhendries JP, Dain E,
et al. Lower protein content in infant formula reduces BMI and obesity risk at
school age: follow-up of a randomized trial. Am J Clin Nutr 2014;99:
1041e51.
[188] Hoelscher DM, Kirk S, Ritchie L, Cunningham-Sabo L. Position of the academy
of nutrition and dietetics: interventions for the prevention and treatment of
pediatric overweight and obesity. J Acad Nutr Diet 2013;113:1375e94.
[189] Butryn ML, Phelan S, Hill JO, Wing RR. Consistent self-monitoring of weight:
a key component of successful weight loss maintenance. Obesity 2007;15:
3091e6.
[190] Steinberg DM, Bennett GG, Askew S, Tate DF. Weighing every day matters:
daily weighing improves weight loss and adoption of weight control be-
haviors. J Acad Nutr Diet 2015;115:511e8.
[191] Dixon H, Scully M, Durkin S, Brennan E, Cotter T, Maloney S, et al. Finding the
keys to successful adult-targeted advertisements on obesity prevention: an
experimental audience testing study. BMC Public Health 2015:15.
[192] Comans TA, Whitty JA, Hills AP, Kendall E, Turkstra E, Gordon LG, et al. The
cost-effectiveness and consumer acceptability of taxation strategies to
reduce rates of overweight and obesity among children in Australia: study
protocol. BMC Public Health 2013;13:1182.
[193] Abete I, Astrup A, Martínez JA, Thorsdottir I, Zulet MA. Obesity and the
metabolic syndrome: role of different dietary macronutrient distribution
patterns and speciﬁc nutritional components on weight loss and mainte-
nance. Nutr Rev 2010;68:214e31.
[194] Aller EEJG, Larsen TM, Claus H, Lindroos AK, Kafatos A, Pfeiffer A, et al.
Weight loss maintenance in overweight subjects on ad libitum diets with
high or low protein content and glycemic index: the DIOGENES trial 12-
month results. Int J Obes Relat Metab Disord 2014;38:1511e7.
[195] Pirozzo S, Summerbell C, Cameron C, Glasziou P. Advice on low-fat diets for
obesity. Protocols 2002;(2). CD003640, Wiley-Blackwell.
[196] Hooper L, Abdelhamid A, Moore HJ, Douthwaite W, Skeaff CM,
Summerbell CD. Effect of reducing total fat intake on body weight: sys-
tematic review and meta-analysis of randomised controlled trials and cohort
studies. BMJ 2012;345. e7666-e.
[197] Te Morenga L, Mallard S, Mann J. Dietary sugars and body weight: systematic
review and meta-analyses of randomised controlled trials and cohort
studies. BMJ 2012;346. e7492-e.
S.C. Bischoff et al. / Clinical Nutrition 36 (2017) 917e938 937
22
[198] Kosoglou T, Hubbell J, Cutler DL, Johnson-Levonas AO, Xu D, Kantesaria BS,
et al. Hypothalamic-pituitary-adrenal axis effects of mometasone furoate/
formoterol fumarate vs ﬂuticasone propionate/salmeterol administered
through metered-dose inhaler. Chest 2013;144:1795.
[199] Malik VS, Pan A, Willett WC, Hu FB. Sugar-sweetened beverages and weight
gain in children and adults: a systematic review and meta-analysis. Am J Clin
Nutr 2013;98:1084e102.
[200] Abargouei AS, Janghorbani M, Salehi-Marzijarani M, Esmaillzadeh A. Effect of
dairy consumption on weight and body composition in adults: a systematic
review and meta-analysis of randomized controlled clinical trials. Int J Obes
Relat Metab Disord 2012;36:1485e93.
[201] Chen M, Pan A, Malik VS, Hu FB. Effects of dairy intake on body weight and
fat: a meta-analysis of randomized controlled trials. Am J Clin Nutr 2012;96:
735e47.
[202] ThomasD, Elliott EJ, Baur L. Lowglycaemic indexor lowglycaemic loaddiets for
overweight and obesity. Cochrane Database Syst Rev 2007;(3). CD005105,
Wiley-Blackwell.
[203] Hauner H, Moss A, Berg A, Bischoff SC, Colombo-Benkmann M, Ellrott T, et al.
Interdisciplinary guideline of S3 quality on prevention and therapy of
obesity. Adipositas 2014;8:179e221.
[204] NICE. Weight management: lifestyle services for overweight or obese adults.
NICE guidelines [PH53]. 2014.
[205] SIGN. Management of obesity. SIGN guideline 115. 2010.
[206] Bischoff SC, Damms-Machado A, Betz C, Herpertz S, Legenbauer T, L€ow T,
et al. Multicenter evaluation of an interdisciplinary 52-week weight loss
program for obesity with regard to body weight, comorbidities and quality of
lifeda prospective study. Int J Obes Relat Metab Disord 2011;36:614e24.
[207] Furlow EA, Anderson JW. A systematic review of targeted outcomes associ-
ated with a medically supervised commercial weight-loss program. J Am
Diet Assoc 2009;109:1417e21.
[208] Hemmingsson E, Johansson K, Eriksson J, Sundstrom J, Neovius M, Marcus C.
Weight loss and dropout during a commercial weight-loss program
including a very-low-calorie diet, a low-calorie diet, or restricted normal
food: observational cohort study. Am J Clin Nutr 2012;96:953e61.
[209] Bazzano LA, Hu T, Reynolds K, Yao L, Bunol C, Liu Y, et al. Effects of low-
carbohydrate and low-fat diets. Ann Intern Med 2014;161:309.
[210] Miller CT, Fraser SF, Levinger I, Straznicky NE, Dixon JB, Reynolds J, et al. The
effects of exercise training in addition to energy restriction on functional
capacities and body composition in obese adults during weight loss: a sys-
tematic review. PLoS One 2013;8:e81692.
[211] Astrup A, Rossner S. Lessons from obesity management programmes: greater
initial weight loss improves long-term maintenance. Obes Rev 2000;1:17e9.
[212] Purcell K, Sumithran P, Prendergast LA, Bouniu CJ, Delbridge E, Proietto J. The
effect of rate of weight loss on long-term weight management: a randomised
controlled trial. Lancet Diabetes Endocrinol 2014;2:954e62.
[213] Ross Middleton KM, Patidar SM, Perri MG. The impact of extended care on
the long-term maintenance of weight loss: a systematic review and meta-
analysis. Obes Rev 2011;13:509e17.
[214] Puzziferri N, Roshek TB, Mayo HG, Gallagher R, Belle SH, Livingston EH. Long-
term follow-up after bariatric surgery. J Am Med Assoc 2014;312:934.
[215] Sj€ostr€om L, Lindroos A-K, Peltonen M, Torgerson J, Bouchard C, Carlsson B,
et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bar-
iatric surgery. N Engl J Med 2004;351:2683e93.
[216] Apovian CM, Aronne LJ, Bessesen DH, McDonnell ME, Murad MH, Pagotto U,
et al. Pharmacological management of obesity: an endocrine society clinical
practice guideline. J Clin Endocrinol Metab 2015;100:342e62.
[217] Jones BJ, Bloom SR. The new era of drug therapy for obesity: the evidence
and the expectations. Drugs 2015;75:935e45.
[218] Yanovski SZ, Yanovski JA. Long-term drug treatment for obesity. J Am Med
Assoc 2014;311:74.
[219] Bray GA, Ryan DH. Medical therapy for the patient with obesity. Circulation
2012;125:1695e703.
[220] Dhurandhar EJ, Keith SW. The aetiology of obesity beyond eating more and
exercising less. Best Pract Res Clin Gastroenterol 2014;28:533e44.
[221] Tang-Peronard JL, Andersen HR, Jensen TK, Heitmann BL. Endocrine-dis-
rupting chemicals and obesity development in humans: a review. Obes Rev
2011;12:622e36.
[222] Buchwald H, Oien DM. Metabolic/bariatric surgery worldwide 2011. Obes
Surg 2013;23:427e36.
[223] Mingrone G, Panunzi S, De Gaetano A, Guidone C, Iaconelli A, Leccesi L, et al.
Bariatric surgery versus conventional medical therapy for type 2 diabetes.
N Engl J Med 2012;366:1577e85.
[224] Schauer PR, Kashyap SR, Wolski K, Brethauer SA, Kirwan JP, Pothier CE, et al.
Bariatric surgery versus intensive medical therapy in obese patients with
diabetes. N Engl J Med 2012;366:1567e76.
[225] Brethauer SA, Aminian A, Romero-Talam�as H, Batayyah E, Mackey J,
Kennedy L, et al. Can diabetes Be surgically cured? Long-term metabolic
effects of bariatric surgery in obese patients with type 2 diabetes mellitus.
Ann Surg 2013:1.
[226] Romeo S, Maglio C, Burza MA, Pirazzi C, Sjoholm K, Jacobson P, et al. Car-
diovascular events after bariatric surgery in obese subjects with type 2
diabetes. Diabetes Care 2012;35:2613e7.
[227] Sj€ostr€om L, Peltonen M, Jacobson P, Sj€ostr€om CD, Karason K, Wedel H, et al.
Bariatric surgery and long-term cardiovascular events. J Am Med Assoc
2012;307:56.
[228] Iaconelli A, Panunzi S, De Gaetano A, Manco M, Guidone C, Leccesi L, et al.
Effects of bilio-pancreatic diversion on diabetic complications: a 10-year
follow-up. Diabetes Care 2011;34:561e7.
[229] Driscoll S, Gregory DM, Fardy JM, Twells LK. Long-term health-related
quality of life in bariatric surgery patients: a systematic review and meta-
analysis. Obesity 2015;24:60e70.
[230] Genton L. Calorie and macronutrient requirements for physical ﬁtness. E-
spen 2011:e77e84.
[231] Garber CE, Blissmer B, Deschenes MR, Franklin BA, Lamonte MJ, Lee IM, et al.
American College of Sports Medicine position stand. Quantity and quality of
exercise for developing and maintaining cardiorespiratory, musculoskeletal,
and neuromotor ﬁtness in apparently healthy adults: guidance for pre-
scribing exercise. Med Sci Sports Exerc 2011;43:1334e59.
S.C. Bischoff et al. / Clinical Nutrition 36 (2017) 917e938938
